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ABSTRACT 
The integrity of genomic DNA is constantly challenged by endogenous and 
environmental agents with the formation of DNA adducts. Some of these adducts are 
toxic and mutagenic to replication, thus potentially leading to cancer and other genetic 
diseases.  To counteract the undesired DNA modifications from damaging agents, 
cells have evolved a number of repair pathways, such as base-excision repair, 
nucleotide-excision repair, mismatch repair, and direct reversal repair, to restore the 
intact DNA.  However, DNA repair is not always efficient, there are many interfering 
factors, such as inherited deficiency in DNA repair pathways, or the abnormal uptake 
of substance with inhibitory effects to DNA repair enzymes that may result in the 
accumulation of DNA adducts. In the meantime, cells have equipped with mechanisms 
to carry out translesion bypass of DNA adducts, and the bypass of these adducts may 
lead to mutagenesis.  Therefore, studying the DNA adduct formation, repair, and other 
mutagenic consequences can shed light on how DNA damaging agents impact on 
cellular response of organisms. A comprehensive understanding of the biological 
outcomes of interested DNA adducts requires the development of a set of efficient 
chemical approaches to prepare and characterize adduct-containing DNA 
oligonucleotides. On the other hand, the biological evaluation of these DNA adducts 
from various aspects, such as studying their genotoxic effects, and exploring potential 
interfering factors to their cellular repair, is essential for providing insights into the 
etiology of many diseases including cancer. 
This dissertation describes the chemical synthesis, characterization, and 
biological evaluation of methylation and glycation DNA adducts by using a variety of 
 
 
chemical and genetic tools. These strategies along with the findings obtained from the 
application of them are briefly discussed in the abstract of four manuscripts as 
following, and are described in detail in CHAPTER 1, 2, 3, and 4. 
In MANUSCRIPT-I, the objective of this study was to develop a rigorous 
procedure to chemically synthesize and characterize adduct-containing DNA 
oligonucleotides for biological studies. Oligonucleotides serve as important tools for 
biological, chemical, and clinical research. The preparation of oligonucleotides 
through automated solid-phase synthesis is well-established. However, identification 
of byproducts generated from DNA synthesis, especially from oligonucleotides 
containing site-specific modifications, is sometimes challenging. Typical high-
performance liquid chromatography, mass spectrometry, and gel electrophoresis 
methods alone are not sufficient for characterizing unexpected byproducts, especially 
for those having identical or very similar molecular weight to the products. We 
developed a rigorous quality control procedure to characterize byproducts generated 
during oligonucleotide syntheses: (1) purify oligonucleotides by different HPLC 
systems; (2) determine exact molecular weight by high-resolution MS; (3) locate 
modification position by MS/MS or exonuclease digestion with matrix-assisted laser 
desorption ionization-time of flight analysis; and (4) conduct, where applicable, 
enzymatic assays. We applied these steps to characterize byproducts in the syntheses 
of oligonucleotides containing biologically important methyl DNA adducts 1-
methyladenine and 3-methylcytosine. In 1-methyladenine synthesis, we differentiated 
a regioisomeric byproduct 6-methyladenine, which possesses a molecular weight 
identical to uncharged 1-methyladenine. As for 3-methylcytosine, we identified a 
 
 
deamination byproduct 3-methyluracil, which is only 1 Da greater than uncharged 3-
methylcytosine in the ∼4900 Da context. The detection of these byproducts would be 
very challenging if the abovementioned procedure was not adopted.   
In MANUSCRIPT-II, as we have developed a platform enabling us to conduct in 
vitro synthesis and quality control of interested DNA adducts, we synthesized a 
number of N-methyl DNA adducts occurring at the Watson-Crick base-pairing face of 
the four nucleobases including 1-methyladenine, 3-methylcytosine, 1-methylguanine, 
and 3-methylthymine. We evaluated the repair preference of AlkB family DNA repair 
enzymes on these N-methyl DNA adducts under difference strand context.  The AlkB 
protein is a repair enzyme that uses an α-ketoglutarate/Fe(II)-dependent mechanism to 
repair alkyl DNA adducts. AlkB has been reported to repair highly susceptible 
substrates, such as 1-methyladenine and 3-methylcytosine, more efficiently in single 
strand-DNA than in double strand-DNA. Here, we tested the repair of weaker AlkB 
substrates 1-methylguanine and 3-methylthymine and found that AlkB prefers to 
repair them in double strand-DNA. We also discovered that AlkB and its human 
homologues, ALKBH2 and ALKBH3, are able to repair the aforementioned adducts 
when the adduct is present in a mismatched base pair. These observations demonstrate 
the strong adaptability of AlkB toward repairing various adducts in different 
environments. 
In MANUSCRIPT-III, we aimed to explore the potential interfering effects of 
the overconsumption of substance from environmental resources to DNA repair. We 
studied the inhibitory activity of a class of natural products, hydrolysable tannins, on 
ALKBH2 enzyme. Hydrolysable tannins are a class of polyphenolic compounds 
 
 
commonly found in many plants. In this work, we studied the in vitro inhibitory 
mechanism of six molecules on ALKBH2. We determined the IC50 values of these 
compounds on the repair of 3-methylcytosine, the proto-typical substrate of ALKBH2. 
A structure-activity relationship was also observed between the strength of inhibition 
and the number of galloyl moieties in a molecule. In addition, we found that the 
inhibition by this class of polyphenolic compounds on ALKBH2 is through an iron-
chelating mechanism.  Direct reversal of alkyl DNA adducts by AlkB family enzymes 
constitute an important cellular repair mechanism for maintaining genome integrity.  
We here demonstrated that the potential effect of overdosing hydrolysable tannins 
might lead to the inhibition of iron-dependent AlkB family enzymes. 
In MANUSCRIPT-IV,  the objective of this work was to explore the in vitro 
synthesis and the in cell biological outcomes of glycation DNA adducts generated 
from cellular reducing sugar glucose-6-phosphate. We chemically synthesized and 
characterized the Amadori glycation products from glucose-6-phosphate and evaluated 
their toxic and mutagenic properties in cell.  Reducing sugars and their metabolic 
derivatives (e.g. D-glucose, D- glucose-6-phosphate, methylglyoxal, and glyoxal) can 
non-enzymatically react with cellular biomacromolecules, such as proteins and nucleic 
acids, to induce glycation. Glucose and glucose-6-phosphate have been shown to 
glycate lysine residues of protein to form Amadori adducts. As a glycating agent with 
multiple-fold higher reactivity and much more abundant cellular concentration than 
glucose, glucose-6-phosphate has also been proposed to glycate DNA and cause 
genotoxicity with the formation of Amadori adducts. Due to the unstable nature of 
Amadori DNA adducts and a number of potential repair pathways, it is challenging to 
 
 
study their toxic and mutagenic properties in cell.  Therefore, the specific biological 
outcomes of these adducts remain unclear.  In this work, we used a number of 
chemical and genetic approaches and studied the biological consequences, such as 
replication block and mutations, of Amadori DNA adducts in a site-specific manner. 
Our data showed that Amadori DNA adducts arising from glucose-6-phosphate can 
induce G to T and single nucleotide deletion, which may lead to devastating biological 
consequences if left unrepaired, thereby affecting the genome integrity of organisms. 
In summary, this dissertation offers a systematic strategy to conduct both in vitro 
and in cell studies of DNA adducts and mutagenesis. The methods applied in this work 
will not only broaden the basic research for chemical modification of nucleic acids, 
but also bring new aspects for studying DNA biology. 
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ABSTRACT 
Oligonucleotides serve as important tools for biological, chemical, and medical 
research.  The preparation of oligonucleotides through automated solid-phase 
synthesis is well established.  However, identification of byproducts generated from 
DNA synthesis, especially from oligonucleotides containing site-specific 
modifications, is sometimes challenging.   Typical HPLC, Mass Spectrometry (MS), 
and gel electrophoresis methods alone are not sufficient for characterizing unexpected 
byproducts, especially for those having identical or very similar molecular weight 
(MW) to the products.  We used a rigorous quality control procedure to characterize 
byproducts generated during oligonucleotide syntheses: 1) purify oligonucleotide by 
different HPLC systems; 2) determine the exact MW by high resolution MS; 3) locate 
modification position by MS/MS or exonuclease digestion with MALDI-TOF 
analysis; and 4) conduct, where applicable, enzymatic assays.  We applied these steps 
to characterize byproducts in the syntheses of oligonucleotides containing important 
methyl DNA adducts 1-methyladenine (m1A) and 3-methylcytosine (m3C).  In m1A 
synthesis, we differentiated a regioisomeric byproduct 6-methyladenine, which 
possesses identical MW to m1A.  As for m3C, we identified a deamination byproduct 
3-methyluracil, which is only 1 Dalton greater than m3C in the ~ 4,900 Dalton 
context.  The detection of these byproducts would be very challenging if the 
abovementioned procedure were not adopted. 
INTRODUCTION 
Oligonucleotides synthesized chemically are widely used as drugs and research 
tools in biology, chemistry, and medicine.  Solid phase synthesis of DNA and RNA 
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oligonucleotides has been well developed and automated phosphoramidite-based 
chemical process has become highly efficient.1–3  Phosphoramidites of regular and 
some modified nucleotides are commercially available and certain oligonucleotide 
strands could be readily obtained from commercial sources.4–7  Besides the great 
development in the synthesis of oligonucleotides, the differentiation of byproducts 
from the product oligonucleotides, especially on those containing site-specifically 
modified structures, is sometimes ignored by the end users.  If those byproducts or 
small impurities were not identified and removed, it could have devastating 
consequences for the corresponding biological assays and medical treatments.8,9  For 
certain instances, it is challenging to identify some byproducts generated in the 
synthesis and deprotection steps, especially those byproducts that have identical or 
very similar MW to the desired product oligonucleotide. 
We have synthesized various oligonucleotides containing modified structures in 
the past, focusing on alkyl or aryl DNA adducts, by using solid and solution phase 
DNA synthesis.10–14  In the syntheses of oligonucleotides containing 1-methyladenine 
(m1A) and 3-methylcytosine (m3C), we observed byproducts are either regioisomer 
(identical MW) to the product or have 1 Dalton in MW greater than the product in a ~ 
4,900 Dalton context (Figure 1a).  m1A and m3C are formed by exogenous and 
endogenous alkylating agents mainly in single-stranded DNA and have been detected 
both in vitro15–21 and in vivo15,20,22–29.  Both adducts are cytotoxic and block DNA 
replication, and are the best substrates for the AlkB family DNA repair enzymes 
(Figure 1b).30–34  m3C has also been proposed an epigenetic biomarker for cancer.35  
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Most of our DNA syntheses successfully provided target oligonucleotides.  
However, some oligonucleotides contained side reaction contaminants generated 
during the synthesis or deprotection steps, requiring further purification and 
identification.  To that end, we applied a rigorous quality control process which entails 
the following steps: i) Synthesize an adduct-containing oligonucleotide from the 
corresponding phosphoramidite; ii) purify the product oligonucleotide by both reverse 
phase and anion exchange HPLC; iii) measure the exact MW of the oligonucleotide by 
high resolution MS (HR-MS), certain impurities can also be detected by HR-MS; iv) 
determine the modification position by either MS/MS or exonuclease digestion with 
MALDI-TOF analysis; and v) test the biological activity of the adduct-containing 
oligonucleotide by appropriate enzymatic assays.   We are assuming that the modified 
nucleotide has been extensively investigated for its stability under solid-phase 
chemical synthesis and deprotection beforehand; however, the strategy outlined above 
should confirm this.  Nuclear Magnetic Resonance (NMR; 1H, 13C, and 31P) is a 
powerful tool for structural integrity studies of the phosphoramidite on the milligram 
scale.36–38  However, NMR becomes impractical for characterizing minor impurities 
within the modified structures in synthetic oligonucleotides due to increasing spectral 
complexity, as well as the final amount of material available (e.g. on a micro-mole or 
less scale).  Below, we report the detailed characterization of byproducts in the 
syntheses of oligonucleotides containing m1A and m3C.  The characterization and 
separation of those byproducts provides confidence in the quality of oligonucleotides 
used in further biological experiments.  
EXPERIMENTAL SECTION 
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Synthesis of Oligonucleotides Containing m1A and m3C.  Oligonucleotides 
(16mer) with the sequence 5’-GAAGACCTXGGCGTCC-3’ containing the lesions at 
X position were made by using solid-phase phosphoramidite chemistry on a 
MerMade-4 Oligonucleotide Synthesizer.10,34,39  The phosphoramidites were purchased 
from ChemGenes.  N1-Methyl deoxyadenosine (n-fmoc) phosphoramidite was used 
for m1A synthesis.  N3-Methyl deoxycytidine (n-bz) phosphoramidite was used for 
m3C synthesis.  The final cleavage and deprotection step was usually carried out by 
treating the oligonucleotide with concentrated aqueous ammonium hydroxide (28%) at 
80 ℃ for 3 hours.  The modified cleavage and deprotection step for minimizing the 
byproduct formation was at 25℃ for 16 h.  The concentration of an oligonucleotide 
was determined by measuring UV absorbance at 260 nm.  The extinction coefficient (ε) 
of a certain adduct is calculated as its unmodified counterpart due to the slight 
variation between the values in the context of a 16mer DNA.   
Purity Test of Oligonucleotides Containing m1A and m3C and Related 
Byproducts by HPLC.  The purity of oligonucleotides was tested by both reverse 
phase (C18) and anion exchange HPLC methods. For the reverse phase test, liquid 
chromatographic separation was performed by using a Phenomenex Luna Semi-
Preparative C18 column (9 x 250 mm, 5 µm) at a flow rate of 3 mL/min.  Solvent A 
was 100 mM triethylammonium acetate in water and solvent B was 100% acetonitrile.  
A solvent gradient was carried out under the following conditions: 2.0% of B for 0.2 
min, 2.0 to 9.0% of B over 0.3 min, 9.0 to 9.4% of B over 16 min, 9.4 to 70.0% of B 
over 0.5 min, 70.0% of B for 3 min, 70.0 to 2.0% of B over 0.5 min, and 2.0 % B over 
4.5 min. The column oven was set at 40 ℃. The UV signal at 260 nm was used to 
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detect the oligonucleotide absorbance.  For the anion exchange LC analysis, 
oligonucleotides were purified and tested by using a Thermo DNAPac PA-100 anion 
exchange column (4 x 250 mm, 13 µm) with solvent A as water and solvent B as 1.5 
M ammonium acetate in water.  A solvent gradient was carried out under the 
following conditions: 50.0% of B for 1 min, 50.0 to 52.0% of B over 2 min, 52.0 to 
75.0% over 1 min, 75.0% of B for 2 min, 75.0 to 50.0% of B over 0.5 min, and 50.0% 
of B for 4.5 min.  The flow rate was at 4.0 ml/min. 
HPLC-MS Analysis.  High resolution MS analyses of oligonucleotides were 
performed on AB Sciex triple quadrupole-TOF mass spectrometers (ABI4600 and 
ABI5600).  ESI was conducted by using a needle voltage of 4.0 kV in a negative ion 
mode.  A heated capillary was set at 600 ℃.   The nebulizer gas pressure was 40 psi; 
the heater gas pressure was 40 psi; the curtain gas pressure was 25 psi; the 
declustering potential was -220 V; and the collision energy was -10 V.  Liquid 
chromatographic separation was performed using a Phenomenex Luna C 18 column 
(4.6 × 100 mm; 5 µm) at a flow rate 0.4 mL/min.  Solvent A was 10 mM ammonium 
acetate in water and solvent B was 100% acetonitrile.  A solvent gradient was carried 
out under the following conditions: 2.0% of B for 0.5 min, 2.0 to 17.4% of B over 
11min, 17.4 to 60.0% of B over 0.1 min, 60.0% of B for 2 min, 60.0 to 2.0% of B over 
0.1 min, and 2.0 % B over 3.3 min.   
MS/MS Analysis.  Oligonucleotide fragmentation analyses were performed by 
manually injecting the oligonucleotide samples of 100 pmol/µl into AB Sciex triple 
quadrupole-TOF mass spectrometers (ABI4600 and ABI5600).  The syringe flow rate 
was set at 10 µl/min.  ESI was conducted by using a needle voltage of 4.5 kV in a 
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negative ion mode.  A heated capillary was set at 400 ℃.  The nebulizer gas pressure 
was 75 psi; the heater gas pressure was 25 psi; the curtain gas pressure was 25 psi; the 
declustering potential was -100 V; and the collision energy was -15 V.  The parent ion 
m/z for m6A, m1A, m3C and m3U were selected as 816.14 (-6 charge), 816.14 (-6 
charge), 974.77 (-5 charge) and 974.96 (-5 charge), respectively.  Data analyses were 
performed with the AB Sciex Analyst TF software 1.7. 
Exonuclease Digestion with MALDI-TOF Analysis.  The modified 
oligonucleotides were characterized by 3’-5’exonuclease digestion followed by 
MALDI-TOF analysis.  In general, 1.0 μL of sample containing 200-250 pmol of a 
modified oligonucleotide was used for digestion.  SVP (0.2 unit) was added together 
with 6.0 μL of ammonium citrate (100 mM, pH 9.4) and 6.0 μL of water for the 3′ to 
5′ digestion.11  For the MALDI-TOF analyses, 1.0 μL of the mixture was used at a 
certain time point until the digestion was almost finished; the digestion was quenched 
by mixing with 1.0 μL of MALDI analysis matrix (3-hydroxypicolinic acid and di-
ammonium hydrogen citrate in a 1:1 ratio).  Samples were analyzed by a Shimadzu 
Axima Performance MALDI-TOF mass spectrometer using a 50Hz laser with a power 
setting of 90 in positive ion reflection mode with 500 shots collected.13  
Enzymatic Reaction with the AlkB protein and HPLC Analysis.  All reactions 
were performed at 37 ℃ for 1 h in a reaction buffer containing 70.0 μM 
Fe(NH4)2(SO4)2·6H2O, 0.93 mM α-ketoglutarate, 1.86 mM ascorbic acid, and 46.5 
mM HEPES (pH 8.0).10  The reactions were quenched by adding 10.0 mM EDTA 
followed by heating at 95 ℃ for 5 min.  Typically, 0.25 µM of the purified AlkB 
protein was incubated with 5.0 µM m6A and m1A in the presence of all cofactors in a 
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20 μL reaction volume.  For the m3C and m3U, 0.18 µM of AlkB was incubated with 
5.0 µM of oligonucleotides.  Samples were then analyzed under an HPLC condition 
that was able to separate the substrate and product.  
To separate the starting material and product of the enzymatic reactions for the 
four lesions, different HPLC conditions were optimized by using either C18 or anion 
exchange columns.  The UV detection was set at 260 nm.  Specifically, (1) m6A and 
its repaired product A were analyzed by using a Phenomenex Luna Semi-Preparative 
C18 column (10 x 150 mm, 5 µm) under the following conditions: Solvent A was 100 
mM triethylammonium acetate in water and solvent B was 100% acetonitrile.  A 
solvent gradient was carried out under the following conditions: 2.0% of B for 0.2 min, 
2.0 to 9.0% of B over 0.3 min, 9.0 to 9.4% of B over 16 min, 9.4 to 70.0% of B over 
0.5 min, 70.0% of B for 3 min, 70.0 to 2.0% of B over 0.5 min, and 2.0 % B for 4.5 
min.  The flow rate was at 3.0 ml/min.  The column oven was set at 40 ℃.  This 
protocol was also used to analyze m3U and its repair product U.  (2) m1A and its 
repaired product A were analyzed by using a Thermo DNAPac PA-100 anion 
exchange column (4 x 250 mm, 13 µm) with solvent A as water and solvent B as 1.5 
M ammonium acetate in water.  A solvent gradient was carried out under the 
following conditions: 50.0% of B for 1 min, 50.0 to 52.0% of B over 2 min, 52.0 to 
75.0% over 1 min, 75.0% of B for 2 min, 75.0 to 50.0% of B over 0.5 min, and 50.0% 
of B for 4.5 min.  The flow rate was at 4.0 ml/min.  (3) m3C and its repaired product C 
were analyzed with a similar protocol to m1A/A analysis, except the solvent gradient 
was changed to the following conditions: 50.0% of B for 1 min, 50.0 to 57.0% of B 
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over 1 min, 57.0% of B for 2 min, 57.0 to 50.0% of B for 0.5 min, then 50.0% of B for 
4.5 min. 
RESULTS  
Identification of m6A Byproduct from m1A Synthesis.  We were trying to 
incorporate m1A into an oligonucleotide as a substrate for the AlkB repair reaction.34,40  
A 16mer oligonucleotide containing m1A was prepared by using the commercially 
available phosphoramidite of m1A (Figure 1a).  The final product was deprotected 
under standard conditions by treating the crude oligonucleotide with ammonium 
hydroxide at 80 ℃ for 3h.  The oligonucleotide was then tested by both reverse phase 
and anion exchange HPLC (see Experimental Procedures for detailed conditions).  
The resulting chromatograms showed a single peak under both conditions (retention 
time 10.2 min in Figure 2a and 4.0 min in Figure S22).  High resolution ESI-TOF MS 
analysis of the sample exhibited m/z at 1224.715 at its -4 charge state, which is in 
good agreement with the theoretical m/z 1224.711 expected of the product 
oligonucleotide (Figure 3a, S1 and Table 1). 
Collision-induced-dissociation (CID) MS/MS analysis was used to determine the 
location of the alkyl adduct in the synthesis of m1A-containing 16mer oligonucleotide 
(Figure 4).  The MS/MS results, presented in detail in the supporting information 
(Figures S5 and Tables S1), confirmed that modification occurred at the eighth 
position from the 3’ end of the oligonucleotide and the modified base had the same 
MW as m1A.  Analysis of 3’ end fragmentations indicated that w15 to w8 fragments all 
contain an extra methyl modification (Figure 4, Table S1 and Figure S10).  On the 
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other hand, w7 to w1 ions showed only standard DNA sequences without methyl 
modification (Table S1).  These results suggested the modification is located between 
w8 and w7, which is the eighth position from the 3’ end of the 16mer oligonucleotide.  
From the 5’ fragmentations, we observed the methyl modification in ions from (a15-C) 
to (a10-G), but no such modification from ion (a9-X) to (a2-A) (Figure 4, Figure S9 and 
Table S1).  These results suggested the modification is located between (a10-G) and 
(a9-X), which is the ninth position from the 5’ end (Figure 4).  The fragmentation 
patterns from both the 5’ and 3’ ends are consistent with the proposed m1A-containing 
DNA sequence (Figure 4).   
To further confirm the location of the modified base, we performed enzyme-
digestion coupled with MALDI-TOF MS analysis.11–13,41,42  The procedure has been 
widely used to confirm the location of lesion positions by determining the mass 
changes after partial digestion from the 3’ end by the exonuclease SVP.43–45  Figure 5 
shows the positive ion MALDI-TOF MS spectra of the 3’ to 5’ SVP exonuclease 
digestion of the product oligonucleotide at different time intervals.  The m/z of 4904.2 
at 0 min (before digestion, as a control) indicated the 16mer DNA sequence contained 
a methylated DNA base (theoretical m/z = 4902.9 Dalton, herein theoretical m/z values 
are shown in parentheses after the observed m/z values).  After 1 minute SVP 
digestion, while the product ion disappeared, three new lower masses appeared at m/z 
= 4615.7 (4614.8), 4326.7 (4325.8), and 4022.7 (4021.7), which correspond to the 15, 
14, and 13mer fragments generated from 3’ cleavage, respectively (Figure 5).  The 
signal intensity of three new peaks were significantly increased with the disappearance 
of the original product oligonucleotide ion at m/z = 4904.2.  
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Further digestion resulted in a number of smaller fragments.  In 3 min digestion 
(Figure 5 and S17), the signal of m/z = 3075.1 (3074.6) matches the sequence for the 
fragment that was cleaved one base before the lesion.  The m/z = 2746.4 (2745.5, 
containing a methyl modification), represents the digestion occurring on the 3' side of 
the modified adenine position (Figure 5), which also persisted in the 5 min digestion 
spectrum.  The signal at 2419.1 (2418.5, no methyl modification) in the 3 and 5 min 
digestions represents the fragment generated after liberation of the 
deoxymethyladenosine 5' monophosphate.  Digestions practically stopped at m/z = 
1223.6/8 (1222.3), which represent the m/z of a 4mer nucleotide of the 5’ end.  Taken 
together, these results confirm that the modified structure is a methylated adenine and 
it is at the ninth position of the proposed oligonucleotide from the 5’to 3’ direction. 
The chromatographic and mass spectral evidence presented above indicates that 
the product oligonucleotide could have the MW expected for a 16mer containing the 
m1A adduct in the correct position.  We then tested the repair of this product by the 
AlkB protein, which is an enzyme that repairs various alkylated DNA adducts (Figure 
1b).32,34  The result showed the repair efficiency of this oligonucleotide by AlkB was 
very low, even when 2.5 uM of AlkB was incubated with 5.0 uM product 
oligonucleotide (Figure 6b and Figure S24).  This observation was in contrast to the 
report that m1A is a good substrate of AlkB (eg. 0.2 µM of AlkB is able to repair 5.0 
µM m1A completely in 1 h).10  We suspected that the structure in the product 
oligonucleotide may not be m1A, even though it had an identical MW to m1A.  The 
reverse phase HPLC results also showed an anomalous phenomenon.  For example, 
the positively charged m1A nucleobase34 should be more polar than the natural base 
 
12 
 
adenine and thus have a shorter retention time on a C18 column.  However, the 
opposite was observed: adenine has ashorter retention time than the product (Figure 2a 
and 2c).  It has been reported that 6-methyladenine (m6A) could be generated from a 
Dimroth rearrangement of m1A under basic conditions(Figure 1a and Table 1).34,46 
We therefore conducted a new batch synthesis of m1A under a milder 
deprotection condition (25 ℃ for 16 h).  The product oligonucleotide was eluted as a 
single peak in both HPLC columns (Figure 2b for C18 and Figure 6d for anion 
exchange).  The HPLC retention time in reverse phase HPLC exhibited a shorter 
retention time (8.5 min, Figure 2b) than the non-modified control adenine (9.0 min, 
Figure 2c) or the previous product (10.2 min, m6A, Figure 2a), in good agreement 
with the theory that m1A should be more polar than both A and m6A.   
The MW of the new product was characterized by HR-MS and had the correct 
m/z of m1A at 1224.715 (1224.711) (Figure 3b, S2 and Table 1).  The MS/MS results 
(e.g., the w7, w8, a9-X, and a10-G ions, Figure 4, Figure S6, S11, S12, and Table S2) 
demonstrated the modification is at the ninth position from the 5’ end and it is a 
methylated adenine.  The exonuclease digestion with MALDI-TOF analyses (Figure 
S18 and S21a) also confirmed the location and identity of adduct.  For example, the 
2746.1 (before adduct) and 2418.8 (after adduct) peaks at 3 min digestion in Figure 
S18 were present.  Finally, incubation with AlkB showed an excellent repair 
efficiency against the new product oligonucleotide: 5.0 µM adduct was mostly 
repaired in 1 hr with 0.2 µM enzyme (Figure 6e).10   Taken together, these results 
confirmed the newly synthesized product as a 16mer oligonucleotide containing m1A 
at the ninth position from the 5’ end (Figure 1a). 
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Identification of m3U Byproduct from m3C Synthesis.  We also wanted to 
synthesize an oligonucleotide containing m3C as the substrate for the AlkB family 
DNA repair reactions within the same sequence context as for the m1A 
oligonucleotide (Figure 1a).34,40  After automated synthesis and standard deprotection 
(80 ℃ for 3h), the HPLC chromatogram from a C18 column showed two peaks with 
similar intensities (9.5 min and 11.6 min, Figure 2d), which were readily separated 
(Figure 2e and 2f).  HR-MS analysis showed that the early eluting peak (9.5 min, 
Figure 2e) had an m/z value 1218.703 at -4 charge state (Figure 3c and S3), which is in 
agreement with that of the m/z of the target m3C containing oligonucleotide 
(theoretical m/z 1218.709, Table 1).  The second species at 11.6 min (Figure 2f) 
showed an m/z 1218.957 at its -4 charge state (Figure 3d and S4).  Compared to the 
9.5 min peak, the m/z value of the second species was 0.254 unit higher at the -4 
charge state, indicating that the MW (4,879.850 Dalton) of the second species is 1.016 
Dalton higher than the first one.  This is consistent with the m/z value of an 
oligonucleotide containing m3U at its -4 charge state (1218.955, Table 1).  m3U could 
potentially be generated from deamination of m3C under basic conditions (Figure 
1a).47  The MS/MS results of the two oligonucleotides (e.g., the w7, w8, a9-X, and a10-
G ions, Figure 4, Figure S7, S8, S13 to S16, Table S3, and S4) demonstrated the 
modifications are at the ninth position from the 5’ end.  The exonuclease digestion 
with MALDI-TOF analyses (Figure S19, S20 and S21b) also confirmed the location 
and identity of the adducts.  At 7 minute digestion, signature peaks were 2722.2 
(before adduct) and 2418.8 (after adduct) for m3C (Figure S18); and 2723.3 (before 
adduct) and 2418.7 (after adduct) for m3U (Figure S19).  The C18 HPLC retention 
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time of the two species showed m3C containing oligonucleotide had a shorter 
retention time (9.5 min, Figure 2e) than m3U (11.6 min, Figure 2f).  This result 
indicated m3C is more polar than m3U, which supports that m3C is positively charged 
at pH 7.0 (Figure 1a).34  The AlkB reaction (0.2 µM) on the m3C oligonucleotide 
showed a good repair efficiency: 5.0 µM m3C adduct was mostly repaired to cytosine 
after 1 h (Figure 6h).  This was not the case for m3U containing oligonucleotides 
under a similar condition, which showed almost no repair to m3U (Figure 6k).  These 
observations were consistent with the observations that m3C is a strong substrate but 
m3U is a weak substrate for AlkB under both in vitro and in vivo conditions.34,48 
To avoid the formation of m3U, we carried out a second batch synthesis of m3C 
containing oligonucleotide under a milder deprotection condition (25 ℃ for 16 h).  
This time we observed only the m3C containing species in the HPLC chromatogram 
(similar to Figure 2e).  The identity of the newly synthesized m3C was confirmed by 
the aforementioned spectroscopic and enzymatic tests.  These results indicate that the 
formation of the byproduct m3U was from deamination of m3C catalyzed by harsh 
deprotection conditions (high temperature and alkaline).47,48  Serendipitously, the 
formation of m3U in the first batch of synthesis provides a new method for chemically 
preparing m3U-containing oligonucleotide. 
DISCUSSION 
For the synthesis of m1A, we observed a byproduct m6A, which exhibited 
identical MW and location to m1A.  It is difficult to differentiate m1A and m6A 
without conducting bioassays and careful HPLC retention analysis.  As for m3C, it 
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was the m3U byproduct that showed a 1 Dalton difference in the ~ 4,900 Dalton 
context (Table 1).  The two oligonucleotides could be eluted as a single species in 
HPLC under certain conditions, thus it is imperative to perform high resolution MS 
analysis and enzymatic reaction to distinguish the two products.  For HPLC analysis 
of modified oligonucleotides, we used a combination of two different separation 
systems, such as reverse phase (e.g. C18) and anion exchange chromatography.  For 
example, it is not easy to find a suitable condition for fully separating 16mer 
containing m1A and A with C18 columns (Figure 2b and 2c).  However, it is relatively 
easy to separate them with an anion exchange column, since m1A is positively 
charged at neutral pH but A is not (Figure 1a, 6d and 6f).34  On the other hand, it is not 
easy to distinguish m6A and A under anion exchange condition (Figure S22 and S23) 
because of their neutrality at pH 7.0, but it is possible to separate them on the C18 
column (Figure 2a and 2c). 
The MW of the oligonucleotide can be determined by HR-MS, and the location of 
the modification can be identified by MS/MS or exonuclease digestion with MALDI-
TOF analysis.  To further confirm the identity of the oligonucleotide from a biological 
activity perspective, we recommend running enzymatic reaction on the product.  In 
this work, we used SVP exonuclease to digest all oligonucleotides formed in the 
syntheses.  A specific enzyme for certain types of modification could greatly help 
elucidate the structure of modification.  So we tested the repair efficiency of m1A and 
m3C and their byproducts by the AlkB repair enzyme.32,34  The AlkB protein in E. coli 
is an α-ketoglutarate/Fe(II)-dependent dioxygenase that repairs various alkyl DNA 
adducts, including m1A and m3C (Figure 1).30–32,40,49–51  We found that m1A and m3C 
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are good substrates but m6A and m3U are weak substrates of AlkB.34,48,49  For other 
modified structures, it is highly recommended that a biological or enzymatic assay 
should be adopted for identifying the product.  The reason for adopting an enzymatic 
test is because a byproduct (e.g. m6A) may have an identical MW as the target product 
(e.g. m1A), which may be hard to differentiate by LC and MS analyses, including the 
MS/MS and exonuclease digestion with MALDI-TOF analysis.   
CONCLUSION 
Chemical synthesis of oligonucleotides is important for conducting various 
biological, chemical, and medical research including oligonucleotide drug 
development.  The field of oligonucleotide synthesis has progressed such that DNA 
and RNA containing standard bases can be ordered from commercial sources.  Most of 
these oligonucleotides are in high quality, but it is a good practice to perform quality 
control in order to confirm the products have the correct sequences in high purity.  A 
simple HPLC/MS analysis should be sufficient for most applications.  However, a 
more rigorous and stringent quality control procedure52–54 should be adopted for site-
specifically modified oligonucleotides, such as epigenetic marks, DNA adducts, and 
drug candidates.  In some cases, byproducts are generated from side chemical 
reactions during standard automated synthesis and deprotection steps.   For this reason, 
specific deprotection conditions may be required for preparation of oligonucleotide 
containing modifications, such as epigenetic biomarkers: 5-hydroxymethyl-dC, 5-
formyl-dC, and 5-carboxy-dC.55,56  After synthesis and deprotection, it is even more 
important to carry out a thorough purification and characterization procedure to ensure 
1) complete removal of protecting groups, 2) product having high purity, and 3) 
 
17 
 
modification having the correct position and identity.  In this study, we used a reliable 
and robust procedure to characterize byproducts from m1A and m3C syntheses.  The 
protocol used here could be helpful for identifying byproducts generated from other 
oligonucleotide syntheses. 
FIGURES 
 
 
Figure 1. Oligonucleotide products and byproducts studied in this work.  a) the 
structures of adducts and byproducts from chemical syntheses and b) the alkyl adduct 
m1A, as an example, is repaired in the presence of the AlkB enzyme and necessary 
cofactors. 
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Figure 2. Reverse phase HPLC chromatograms of 16mer DNA alkyl products and 
byproducts.  The retention time of a modification-containing oligonucleotide is labeled 
on top of the corresponding chromatogram.  The modifications are: a) m6A); b) m1A; 
c) A; d) mixture of m3C + m3U; e) m3C; and f) m3U. 
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Figure 3. High resolution ESI-TOF MS analyses of 16mer DNA oligonucleotides 
containing target modifications and byproducts.  Data represent the -4 charge 
envelopes and the monoisotopic peak (all 12C, 14N, etc.) values are labeled above the 
first peak in each peak envelope.  a) The oligonucleotide (containing m6A) generated 
from initial m1A synthesis; b) m1A; c) m3C; and d) m3U.   
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Figure 4. Predicted fragmentation pattern from collision-induced-dissociation of the 
16mer oligonucleotide products from the m1A and m3C syntheses.  X denotes the 
modified nucleotides. 
 
 
Figure 5.  Time-course MALDI-TOF analyses of SVP digestion products of the 
16mer product oligonucleotide (containing m6A) generated from m1A synthesis.  
Theoretical masses are listed in the inset.  The theoretical monoisotopic mass at 
2745.5 is highlighted in red because it is the smallest digestion product containing the 
modification. 
 
 
21 
 
 
Figure 6. HPLC profiles of the AlkB repair reactions on different alkyl substrates.  
The three chromatograms within each panel represent one set of repair reaction 
including the oligonucleotides of starting material, reaction mixture, and product.  For 
example, in the panel containing chromatograms a, b, & c, a) represents the starting 
material m6A, b) represents the repair reaction of m6A by AlkB, and c) represents the 
pure product adenine synthesized separately.  Chromatograms shown in a, b, & c 
relevant to m6A repair and in j, k, & l relevant to m3U repair were analyzed under 
reverse phase conditions.  Chromatograms shown in d, e, & f relevant to m1A repair 
and in g, h, & i relevant to m3C repair were analyzed under anion exchange conditions 
(see Experimental Procedures for detailed information).  a) m6A; b) m6A+AlkB; c) A; 
d) m1A; e) m1A+AlkB; f) A; g) m3C; h) m3C+AlkB; i) C; j) m3U; k) m3U+AlkB; 
and l) U.  
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Figure S1. ESI-TOF analysis of 16mer oligonucleotide containing m6A at -4 charge 
state. 
 
Figure S2. ESI-TOF analysis of 16mer oligonucleotide containing m1A at -4 charge 
state. 
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Figure S3. ESI-TOF analysis of 16mer oligonucleotide containing m3C at -4 charge 
state. 
 
Figure S4. ESI-TOF analysis of 16mer oligonucleotide containing m3U at -4 charge 
state. 
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Figure S5. MS/MS fragmentation analysis of 16mer containing m6A.  The diamond 
marks the parent ion. 
 
Figure S6. MS/MS fragmentation analysis of 16mer containing m1A.  The diamond 
marks the parent ion. 
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Figure S7. MS/MS fragmentation analysis of 16mer containing m3C.  The diamond 
marks the parent ion. 
 
Figure S8. MS/MS fragmentation analysis of 16mer containing m3U.  The diamond 
marks the parent ion. 
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Figure S9. MS/MS fragmentation spectrum of 16mer containing m6A.  The peak 
envelope indicates the a10-G ion at -3 charge state. 
 
Figure S10. MS/MS fragmentation spectrum of 16mer containing m6A.  The peak 
envelope indicates the W8 ion at -4 charge state. 
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Figure S11. MS/MS fragmentation spectrum of 16mer containing m1A.  The peak 
envelope indicates the a10-G ion at -3 charge state. 
 
Figure S12. MS/MS fragmentation spectrum of 16mer containing m1A. The peak 
envelope indicates the W8 ion at -4 charge state. 
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Figure S13. MS/MS fragmentation spectrum of 16mer containing m3C.  The peak 
envelope indicates the a10-G ion at -3 charge state. 
 
Figure S14. MS/MS fragmentation spectrum of 16mer containing m3C.  The peak 
envelope indicates the W8 ion at -3 charge state. 
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Figure S15.  MS/MS fragmentation spectrum of 16mer containing m3U.  The peak 
envelope indicates the a10-G ion at -3 charge state. 
 
Figure S16. MS/MS fragmentation spectrum of 16mer containing m3U. The peak 
envelope indicates the W8 ion at -3 charge state. 
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Figure S17. MALDI-TOF analyses on the exonuclease digestion of 16mer containing 
m6A. 
 
Figure S18. MALDI-TOF analyses on the exonuclease digestion of 16mer containing 
m1A. 
 
Figure S19. MALDI-TOF analyses on the exonuclease digestion of 16mer containing 
m3C. 
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Figure S20. MALDI-TOF analyses on the exonuclease digestion of 16mer containing 
m3U. 
 
 
Figure S21. Detailed MALDI-TOF spectra of oligonucleotides in the exonuclease 
digestion assays.  a) m1A and b) m3C. 
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Figure S22. HPLC analysis of 16mer m6A oligonucleotide under anion exchange 
condition.  The retention time is about 4.0 min. 
 
Figure S23. HPLC analysis of 16mer A oligonucleotide under anion exchange 
condition.  The retention time is about 4.0 min. 
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Figure S24. MS spectra of the AlkB protein repairs 16mer m6A oligonucleotide at -4 
charge state.  Top: 5.0 µM of m6A without addition of AlkB (peak envelope starts at 
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m/z 1224.7).  Bottom: 5.0 µM of m6A with addition of 2.5 µM AlkB and 
corresponding cofactors.  A very small amount of m6A (peak envelope starts at m/z 
1224.7) was repaired to A (peak envelope starts at m/z 1221.2).  
TABLES  
 
Table 1.  Calculated and observed monoisotopic molecular weight and m/z value of 
modified oligonucleotides.  For m1A and m3C synthesis, the sequence of the 16mer 
was 5’-GAAGACCTXGGCGTCC-3’, where X indicates the position of the modified 
bases.   
 
Lesion or base 
MW 
(calculated) 
of neutral 
species 
m/z (calculated) 
-4 charge peak 
m/z (observed) 
-4 charge peak 
16mer m6A 4902.877 1224.711 1224.715 
16mer m1A 4902.877 1224.711 1224.715 
16mer m3C 4878.866 1218.709 1218.703 
16mer m3U 4879.850 1218.955 1218.957 
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Table S1. Observed and predicted m/z for high resolution MS/MS fragmentation 
patterns displayed in Figure S5 of 16mer containing m6A.  Predicted CID fragments 
are shown in Figure 4. 
Fragment Charge Theoretical m/z Observed m/z 
W1 -1 306.049 306.045 
W2 -2 297.044 297.043 
W3 -2 449.067 449.066 
W4 -2 613.593 613.593 
W5 -2 758.116 758.118 
W6 -3 614.759 614.753 
W7 -3 724.443 724.441 
W8 -3 833.468 833.467 
W9 -3 934.816 934.816 
W10 -3 1031.165 1031.170 
W11 -4 845.384 845.379 
W12 -4 923.648 923.645 
W13 -4 1005.911 1005.913 
W14 -5 867.139 867.131 
W15 -5 929.750 929.751 
a2-A -1 426.081 426.079 
a3-A -2 369.066 369.064 
a4-G -2 525.594 525.596 
a5-A -2 690.121 690.119 
a6-C -2 846.650 846.649 
a7-C -3 660.446 660.446 
a9-X -3 858.143 858.145 
a10-G -3 967.168 967.167 
a11-G -3 1076.852 1076.851 
a12-C -4 889.650 889.650 
a13-G -4 961.912 961.911 
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Table S2. Observed and predicted m/z for high resolution MS/MS fragmentation 
patterns displayed in Figure S6 of 16mer containing m1A.  Predicted CID fragments 
are shown in Figure 4. 
Fragment Charge Theoretical m/z Observed m/z 
W1 -1 306.049 306.047 
W2 -2 297.044 297.041 
W3 -2 449.067 449.065 
W4 -2 613.593 613.592 
W5 -2 758.116 758.115 
W6 -3 614.759 614.759 
W7 -3 724.443 724.442 
W8 -3 833.468 833.467 
W9 -3 934.816 934.815 
W10 -3 1031.165 1031.162 
W11 -4 845.384 845.383 
W12 -4 923.648 923.645 
W13 -4 1005.911 1005.909 
W14 -5 867.139 867.134 
W15 -5 929.750 929.750 
a2-A -1 426.081 426.078 
a3-A -2 369.066 369.063 
a4-G -2 525.594 525.594 
a5-A -2 690.121 690.120 
a6-C -2 846.650 846.646 
a7-C -2 991.173 991.174 
a8-T -2 1135.696 1135.701 
a9-X -3 858.143 858.148 
a10-G -3 967.168 967.167 
a11-G -3 1076.852 1076.850 
a12-C -4 889.650 889.647 
a13-G -4 961.912 961.907 
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Table S3. Observed and predicted m/z for high resolution MS/MS fragmentation 
patterns displayed in Figure S7 of 16mer containing m3C.  Predicted CID fragments 
are shown in Figure 4. 
Fragment Charge Theoretical m/z Observed m/z 
W1 -1 306.049 306.049 
W2 -1 595.095 595.095 
W3 -2 449.067 449.065 
W4 -2 613.593 613.593 
W5 -2 758.116 758.118 
W6 -2 922.643 922.644 
W7 -3 724.443 724.444 
W8 -3 825.464 825.464 
W9 -3 926.813 926.816 
W10 -4 767.119 767.117 
W11 -4 839.381 839.380 
W12 -4 917.645 917.647 
W13 -4 999.908 999.911 
W14 -4 1078.173 1078.170 
W15 -4 1156.437 1156.437 
a2-A -1 426.081 426.081 
a3-A -1 739.139 739.140 
a4-G -2 525.594 525.593 
a5-A -2 690.121 690.121 
a6-C -2 846.650 846.652 
a7-C -2 991.173 991.177 
a8-T -2 1135.696 1135.701 
a9-X -3 858.143 858.144 
a10-G -3 959.164 959.162 
a11-G -3 1068.848 1068.851 
a12-C -4 883.647 883.650 
a13-G -4 955.909 955.907 
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Table S4. Observed and predicted m/z for high resolution MS/MS fragmentation 
patterns displayed in Figure S8 of 16mer containing m3U.  Predicted CID fragments 
are shown in Figure 4. 
 
Fragment Charge Theoretical m/z Observed m/z 
W1 -1 306.049 306.047 
W2 -1 595.095 595.092 
W3 -2 449.067 449.066 
W4 -2 613.593 613.593 
W5 -2 758.116 758.114 
W6 -3 614.759 614.758 
W7 -3 724.443 724.444 
W8 -3 825.792 825.791 
W9 -3 927.141 927.141 
W10 -4 767.365 767.362 
W11 -4 839.627 839.627 
W12 -4 917.891 917.887 
W13 -4 1000.154 1000.154 
W14 -4 1078.419 1078.414 
W15 -5 925.145 925.139 
a2-A -1 426.081 426.079 
a3-A -1 739.139 739.137 
a4-G -2 525.594 525.593 
a5-A -2 690.121 690.118 
a6-C -2 846.650 846.648 
a7-C -2 991.173 991.172 
a8-T -2 1135.696 1135.692 
a9-X -2 1287.719 1287.711 
a10-G -3 959.492 959.496 
a11-G -3 1069.176 1069.173 
a12-C -4 883.893 883.889 
a13-G -4 956.155 956.152 
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ABSTRACT 
The AlkB protein is a repair enzyme that uses an α-ketoglutarate/Fe(II)-dependent 
mechanism to repair alkyl DNA adducts.  AlkB has been reported to repair highly 
susceptible substrates, such as 1-methyladenine and 3-methylcytosine, more 
efficiently in ss-DNA than in ds-DNA.  Here, we tested the repair of weaker AlkB 
substrates 1-methylguanine and 3-methylthymine, and found that AlkB prefers to 
repair them in ds-DNA.  We also discovered AlkB and its human homologs, ABH2 
and ABH3, are able to repair the aforementioned adducts when the adduct is present in 
a mismatched base pair.  These observations demonstrate the strong adaptability of 
AlkB on repairing various adducts in different environments. 
INTRODUCTION 
Nuclear DNA is constantly exposed to damage from exogenous and endogenous 
processes, generating a variety of DNA adducts in the genome.1–3  If those adducts 
occur in a single stranded (ss) DNA region, such as at a replication fork, they may 
cause mutations or replication blocks during DNA synthesis.  If the lesions occur in a 
double stranded (ds) context, they may additionally change local DNA architecture, 
leading to an unstable DNA duplex, or possibly disrupt the proper recognition of 
specific sites by sequence-specific DNA binding proteins, such as transcription 
factors.1,2  To avoid these adverse effects from DNA adducts, organisms have 
developed an array of DNA repair pathways that are able to protect cells against 
lesions in both ss- and ds-DNA.  One of these enzymes, the adaptive response protein 
AlkB of E. coli, has been reported to repair alkyl DNA adducts, such as 1-
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methyladenine (m1A) and 3-methylcytosine (m3C), in both ss- and ds-contexts, 
although it prefers repairing lesions in single stranded substrates.4–9 
The AlkB protein was discovered to be a dioxygenase that uses an α-
ketoglutarate/Fe(II)-dependent mechanism to oxidize the aberrant alkyl groups, 
ultimately restoring the undamaged DNA bases (Figure 1a).4,5  Different homologs of 
the E. coli AlkB protein exist in prokaryotic and eukaryotic species; nine such 
homologs exist in human cells (ABH1-8 and FTO).4,5  Among the nine AlkB 
homologs, ABH1 functions as an apyrimidinic/apurinic lyase and nucleic acid 
demethylase.6,7  ABH48,9 and ABH710,11 modify protein substrates and ABH812–16 is a 
tRNA methyltransferase and hydroxylase.  ABH517–21 and FTO22–25 have been 
demonstrated to work on N6-methyladenine (m6A) in RNA or DNA.  ABH22,26–30 and 
ABH331–34 are DNA repair enzymes; and the function of ABH6 remains to be 
established.  Since the discovery of this class of enzymes, a variety of DNA adducts 
have been identified as substrates for AlkB and its mammalian homologs, ABH2 and 
ABH3, both in vitro and in vivo.1,10–13  The adducts include all of the seven N-methyl 
lesions occurring at the Watson-Crick (W-C) base-pairing face of the four 
nucleobases.13  The seven adducts include m1A, m3C, m6A, N4-methylcytosine 
(m4C), 1-methylguanine (m1G), N2-methylguanine (m2G), and 3-methylthymine 
(m3T).  Among these lesions, m6A, m4C and m2G are exocyclic adducts whose 
structures afford the opportunity to avoid disruption of W-C base-pairing by allowing 
the methyl group to swivel away from the H-bond interface.  By contrast, 
m1A/m3C/m1G/m3T have the methyl group on the nucleobase ring, which 
unavoidably will interfere with hydrogen-bond pairing if left unrepaired.  AlkB has 
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also been reported to repair other DNA adducts, such as 3-ethylcytosine (e3C), N2-
ethylguanine, 1,N6-ethenoadenine (εA), 3,N4-ethenocytosine (εC), 1,N2-
ethenoguanine (1,N2-εG), 1,N6-ethanoadenine (EA), 3,N4-α-hydroxyethanocytosine 
(HEC), 3,N4-α-hydroxypropanocytosine (HPC), N2-furan-2-yl-methylguanine, N2-
tetrahydrofuran-2-yl-methylguanine, α-hydroxypropanoguanine, γ-
hydroxypropanoguanine, and malondialdehydeguanine.35–43  The substrate scope and 
repair efficiency of the AlkB family enzymes have been reviewed by several 
papers.1,5,44,45   
EXPERIMENTAL PROCEDURES 
Oligonucleotide synthesis.  Sixteen-mer oligonucleotides (oligos) with the 
sequence 5’-GAAGACCTXGGCGTCC-3’ containing the lesions at X position were 
made by using solid-phase phosphoramidite chemistry36,37,40–42 on a MerMade-4 
Oligonucleotide Synthesizer.  The complementary 17mer oligos were synthesized with 
the sequence of 5’-TGGACGCCYAGGTCTTC-3’, where Y represents the position 
incorporating the regular bases A, C, G and T.  For the ss-23mer unrelated DNA, the 
sequence was 5’-AAAGCTTCTGCAATCAGGTTCAG-3’.  The oligos were purified 
by reverse-phase HPLC with two solvents.  Solvent A was 100 mM 1:1 triethylamine-
acetic acid (TEAA) in water and solvent B was 100% acetonitrile.  The column was 
Phenomenex DNAPac PA-100 Semi-Preparative (9 x 250 mm, 5µm). The 
concentration of DNA was determined by UV absorbance at 260nm.  The extinction 
coefficient (ε) of a certain adduct is calculated as its unmodified counterpart due to the 
negligible variation between the values in the context of a 16-mer DNA.  The oligos 
were characterized by HPLC-electrospray ionization (ESI) triple quadrupole-TOF 
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mass spectrometry (MS) (AB Sciex).  Solvent A was 10mM ammonium acetate in 
water and solvent B was 100% acetonitrile. The column was Phenomenex Luna C 18 
column (4.6 × 100 mm; 5µm).  The calculated and observed monoisotopic MW and 
m/z value of the oligos are shown in Table S1. 
Expression and purification of the AlkB, ABH2 and ABH3 proteins.  The 
AlkB gene was cloned into a pET28a+ vector (EMD Millipore) and then transformed 
into E. coli Rosetta2(DE3)pLysS (EMD Millipore) cells for expression.40,41  The 
expressed protein was purified by affinity column chromatography, HisTrap HP (GE 
Healthcare Life Sciences).  Thrombin (Sigma-Aldrich, 0.005U/10μg protein) was used 
to digest His-tag containing AlkB protein overnight.  Cation-exchange column 
chromatography, HiTrap SP HP (GE Healthcare Life Sciences) was used for further 
purification.  The final purified protein was concentrated by Amicon® Ultra 
Centrifugal Filters (EMD Millipore) and stored in the AlkB storage buffer (10 mM 
Tris, 100 mM NaCl, 1 mM 2-mercaptoethanol, 10% glycerol, pH 8.0).  The ABH2 
and ABH3 proteins were purified using the same procedure, with the exception that 
the E. coli cell used for expression was BL21(DE3)pLysS (EMD Millipore) instead of 
Rosetta2(DE3)pLysS.  The ABH2 and ABH3 proteins were stored in the ABH storage 
buffer (50 mM N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid, 300 
mM NaCl, 10% glycerol, and 1 mM 2-mercaptoethanol, pH 8.0).  Protein standard 
was purchased from Bio-Rad. 
Enzymatic reaction.  All reactions were performed at 37 ℃ for 1h in a reaction 
buffer containing 70 μM Fe(NH4)2(SO4)2·6H2O, 0.93 mM α-ketoglutarate, 1.86 mM 
ascorbic acid, and 46.5 mM HEPES (pH 8.0).37,39,40  The reactions were quenched by 
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adding 10 mM EDTA followed by heating at 95 ℃ for 5 min. Samples were then 
analyzed by HPLC or HPLC-electrospray ionization triple quadrupole-TOF MS (AB 
Sciex). Typically, the purified AlkB, ABH2 and ABH3 proteins were incubated with 5 
µM DNA oligos in the presence of all cofactors in a 20 μL reaction volume.  The 
amount for these enzymes were variable on different substrates as shown in Table S3-
5.  For the double-stranded DNA substrates, 1.5 equivalents (7.5 μM) of the 17mer 
complementary oligo containing A/C/G/T opposite to the adduct was annealed by 
heating the mixture at 80 ℃ for 10 min and then cooled down slowly to room 
temperature; the rest of the reaction was under similar conditions to ss-DNA repair 
reaction.  For the initial velocity measurements, the reactions were stopped at 0, 0.5, 1, 
4, and 10min for m1A and m3C and at 0, 4, 8, and 12 min for m1G and m3T.  For the 
reactions with excessive amount of unrelated DNA, each reaction was carried out with 
5μM substrate and additional 15μM ss-23mer DNA.  The corresponding 
concentrations of the enzymes were listed in Table S5.  Each reaction was carried out 
in triplicate. 
LC-MS analyses.  Oligonucleotide analyses were performed on AB Sciex triple 
quadrupole-TOF mass spectrometer.  ESI was conducted using a needle voltage on 4.0 
kV.  Nitrogen gas was used with a setting of drying 40 L/min and a heated capillary at 
600 ℃.  Liquid chromatographic separation was performed using a Phenomenex Luna 
C 18 column (4.6 × 100 mm; 5µm) at a flow rate 0.4 mL/min.  Solvent A was 10mM 
ammonium acetate in water and solvent B was 100% acetonitrile.40,41  A linear 
gradient was carried out under the following conditions: 2.0% of B for 0.5 min, 2.0 to 
17.4% of B over 11 min, 17.4 to 60.0% of B over 0.1 min, 60.0% of B for 2 min, 60.0 
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to 2.0% of B over 0.1 min, then 2.0 % B over 3.3 min.  The LC analyses were carried 
out with the temperature of the column oven set at 40 ℃.  Data analyses were 
performed with the AB Sciex Analyst TF software 1.7.  The relative amount of the 
starting material and product was quantified by integrating the peak areas of the 
corresponding oligos in the mass spectrum.  In each reaction, we treated 16mer oligo 
containing the starting material had the same ionization efficiency as the 16mer 
product due to the negligible variation between the structures in the context of a 16-
mer DNA. 
Statistical analyses.  All statistical analyses were carried out by IBM SPSS 
Statistics 23 and Microsoft Excel 2013.  Statistical significance for data between two 
groups were performed with Student’s two-tailed t test.  P-value <0.05 was considered 
as statistically significant. 
RESULTS 
AlkB has been reported to repair strong substrates, such as m1A and m3C, more 
efficiently in ss-DNA than in ds-DNA.4–9 However, the strand preference of AlkB for 
some of its weak substrates, such as m1G and m3T, remained unanswered.  In this 
work, we selected four lesions to investigate the repair efficiency of AlkB in both ss- 
and ds-DNA (Figure 1b).  Because these adducts are mutagenic to varying degrees, 
causing misincorporation of non-authentic pairing bases during replication, we also 
tested the ds-DNA conditions with all four DNA bases opposite to each adduct in the 
complementary strand to demonstrate AlkB’s repair capacity under mismatch 
conditions.    ABH2 and ABH3 have been reported to prefer repairing DNA adducts in 
ds- and ss-DNA, respectively, and were also tested on those lesions. 
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The ability of AlkB family enzymes to repair the four methylated bases was 
tested in vitro using a previously reported experimental procedure.12,13 AlkB and its 
human homologs were purified from E. coli cells (Figure S3-5).  Oligos containing the 
four adducts were synthesized by incorporating each adduct into a 16mer oligo in a 
site-specific manner and their purity and identity were characterized by LC-MS 
(Figure S6 and S8-11).11 For each lesion, experiments were conducted both in the 
presence and absence of the repair enzyme with all necessary cofactors, and the 
reaction products were analyzed by high resolution triple quadrupole-TOF MS (Figure 
2).  To test repair efficiency in ds-DNA, each adduct was first annealed to 17mer 
complementary oligos (Figure S7 and S12-15) with all four DNA bases opposite the 
lesion.  To avoid the interference of the complementary oligo with the 16mer starting 
material in the MS spectra, a 17mer complementary oligo was chosen because it has 
~300 Daltons difference in MW than the 16mer oligo.  The 16mer lesion-bearing 
oligos demonstrated a good signal in the -4 charge envelope of the MS spectra (Figure 
2).  To illustrate the MS analysis, the MW of the 16mer containing an m1G lesion is 
calculated as 4918.87 Daltons (Table S1); its monoisotopic peak (all 12C, 14N, 16O, 
etc.) in the -4 charge state has a calculated mass/charge (m/z) of 1228.71. 
Experimentally, we observed a peak at an m/z of 1228.70 (Figure 2c).  The area 
underneath the peak envelopes of the starting material and product were used to 
quantify the conversion of the reaction (Figure 2).   
For each lesion-containing oligo, 5µM starting material was used in the repair 
reaction.  To accurately compare the efficiency of repair for each lesion, the 
concentration of each enzyme was optimized to ensure no reaction proceeded to 100% 
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conversion (Table S3).  Acting upon an m1A lesion in ss-DNA, AlkB converted 53% 
of the starting material to a 16mer product containing A at the lesion site (Figure 2a 
and 3a).  When m1A was annealed to the 17mer oligo containing complementary base 
T, the theoretical perfect match in a repaired state, only 22% of m1A was repaired.  
For m1A paired with mismatched bases, such as A/G/C, the reactions also showed 
lower repair ratios than in ss-DNA (Figure 3a and Table S2).  Similarly, AlkB was 
demonstrated to repair m3C better in ss-DNA than ds-DNA with the exception that 
m3C:A mismatched pair provided a slightly higher repair efficiency (Figure 3b and 
Table S2).  These results were consistent with the previous observations of AlkB’s 
repair of m1A and m3C in ss- and ds-DNA.4–9 
After testing the strong substrates of AlkB (m1A and m3C), the two weak 
substrates m1G and m3T were investigated.  For m1G, 48% of the adduct was 
repaired in ss-DNA, but 69% was repaired when m1G was put opposite to C (Figure 
2c, 2d, 3c, and Table S2).  For the mismatch reactions, complementary base A (50%) 
and T (56%) also showed higher repair ratios than the single-stranded reaction.  For 
m3T repair, the ss-DNA condition (12%) provided the least efficient repair among all 
conditions (Table S2).  The perfect match of m3T with A was repaired 21% and the 
mismatch with C yielded 28% conversion.  Because m1A and m3C are the strong 
substrates of the three enzymes and m1G and m3T are the weak substrates of the 
proteins, the concentrations of the enzymes for different reactions varied significantly 
from 0.08-5.0 μM in the steady state studies (Table S3).  The concentrations were 
optimized to make sure that the repair ratios were significantly different between ss- 
and ds-repair.  The results from m1G and m3T reactions demonstrated AlkB repairs 
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them more efficiently in ds-perfect match conditions than in ss-DNA in the steady 
state studies.  To further support this conclusion, we also measured the initial velocity 
of the repair reactions on the adducts in ss-DNA and in the perfect match ds-DNA 
(Table 1).  The results confirmed the preferential repair of m1G and m3T in ds-DNA, 
and the differences of repair efficiency between ss- and ds-conditions were statistically 
significant.  On the other hand, the initial rates of repair on m1A and m3C were higher 
in ss-DNA than ds-DNA (Table 1). 
The current studies on AlkB’s repair of the four DNA adducts were carried out in 
a 16mer sequence context, which is different from the situation in cell where adducts 
are more likely to be present in parts per thousand or less.  To study the repair of AlkB 
with an excessive amount of non-damaged DNA, the repair reactions were performed 
by adding of an extra 15 μM unrelated ss-23mer DNA oligos.  This condition allowed 
us to decrease the lesion:normal base ratio from 1:15 to 1:84.  The repair efficiency 
also supported the previous conclusions that AlkB prefers to repair m1G and m3T in 
ds-DNA and m1A and m3C in ss-DNA with the repair ratio differences statistically 
significant (Figure S16 and Table S5).  
We also tested the repair of these four adducts by AlkB’s human homologs ABH2 
and ABH3.  For the repair ratios of the four lesions with ABH2, the double stranded 
condition for the perfect match base pairs and most of the mismatch base pairs were 
better repaired than ss-DNA, except the m3C:T mismatched pair (54%), which 
demonstrated a slightly lower repair efficiency than m3C in ss-DNA (60%, Figure S1 
and Table S2).  For the repair of m1A and m3C by ABH3, ss-DNA repair was 
consistently more effective than in ds-DNA (Figure S2 and Table S2).  However, we 
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were not able to detect the reaction products of m1G and m3T because they showed 
very little repair susceptibility, even when ABH3 was present at a very high 
concentration (5 µM, Table S3).  These results were consistent with previous 
observations that ABH2 prefers ds repair and ABH3 prefers ss repair.28,29,46–50 
DISCUSSION 
In the above section, we demonstrated that AlkB is able to repair DNA adducts in 
both ss- and ds-DNA.  AlkB repairs m1A and m3C better in ss-DNA than in ds-DNA 
for most strand conditions.  However, the preference of repairing m1G and m3T is the 
opposite: AlkB prefers to repair these lesions in perfect match and most of the 
mismatch ds-DNA.  AlkB has been reported to repair those four DNA adducts both in 
vitro and in vivo.36,39  It has been demonstrated that m1A and m3C are strong 
substrates for AlkB because both are positively charged under physiological pH 
conditions.35,36  In AlkB deficient cells, m1A and m3C behave as strong replication 
blocks: only ~12% of them could be bypassed by the replication polymerase.36  m1A 
is not mutagenic and m3C is ~ 30% mutagenic with the predominant mutations being 
C to T and C to A.  The existence of AlkB could completely repair m1A and m3C in 
cell, thus fully alleviating their toxicity and mutagenicity.  AlkB can also efficiently 
repair e3C, εA and EA both in vitro and in vivo.36–38,40  On the other hand, m1G, m3T, 
1,N2-εG and εC are weak substrates for AlkB with substantial cytotoxic and 
mutagenic signatures in both AlkB positive and negative cells.36,37,43  For example, 
m1G and m3T are only bypassed less than 10% of the replications in the absence of 
the AlkB protein.  The presence of AlkB only slightly increases the bypass of these 
two adducts.  For mutagenicity, m1G is ~80% mutagenic with G to T, G to A and G to 
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C mutations without the repair of AlkB.  Similarly, m3T is ~60% mutagenic with T to 
A and T to C mutations.  The mutagenicity of m1G and m3T decreases with the 
presence of AlkB.  The cellular results of AlkB’s repair on those four adducts support 
the current observation that m1A and m3C are strong substrates of AlkB, and m1G 
and m3T are weak substrates.  If these two weak substrates are left unrepaired in cell, 
they will not only strongly block replication but also cause a significant increment in 
the percentage and type of mutations.  Based on these observations, we hypothesize 
that AlkB could efficiently repair strong substrates, such as m1A and m3C, in ss-DNA 
before they encounter a polymerase.  In contrast, AlkB cannot efficiently repair weak 
substrates, such as m1G and m3T, when they exist in ss-DNA.  AlkB may have 
evolved to repair the weak substrates better in a ds-DNA context.   This preference 
would avoid mutations to a certain degree, or in combination with mismatch repair, 
could potentially prevent mutations pre- and post-replication.   
Previously, Zhu et al. identified an active site region and key amino acid residues 
that are responsible for the repair of m1A by AlkB and the repair of m6A by FTO and 
ABH5.51  By swapping the active site sequences between the two types of 
demethylases, they found the enhanced activity of not only AlkB on repairing m6A 
but also FTO and ABH5 on m1A.  Similarly, Chen et al. achieved preferential ss-
repair by ABH2 and ds-repair by ABH3 (the opposite strand preference for both of the 
enzymes) by swapping the recognition residues in their structures.27  AlkB has been 
reported to repair different DNA adducts in both ss- and ds-DNA.  Further structural 
analysis should provide valuable information on AlkB’s strand preference of 
m1A/m3C and m1G/m3T.  Besides the strand preference, we also demonstrated that 
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all three enzymes can repair lesions in ds-DNA under mismatch conditions; some of 
the mismatches are even better repaired than the perfect match.  These observations 
demonstrate the strong adaptability of AlkB on repairing various adducts under 
different strand and sequence contexts.  The current studies utilized pH 8.0 and an iron 
concentration that would provide a steady state measurement.  However, Maciejewska 
et. al have shown that AlkB’s repair efficiency depends on the pKa of substrates as 
well as optimal Fe(II) ion concentration.35  They demonstrated the optimal repair of 
m3C and HPC was achieved at pH 7.5, and the optimal repair of HEC was achieved at 
pH 5.8.  Correspondingly, the adducts would be positively charged under the above 
pH conditions.  The preference to positively charged adducts is possibly due to the 
interaction with the negatively charged aspartate residue (Asp135) in the catalytic 
center of AlkB.   On the other hand, the poor repair efficiency on m1G and m3T could 
be explained, at least partially, that the methylated nitrogen atoms in those two adducts 
do not exist in cationic form under any pH condition (not limited to physiologically 
relevant pH range).35,42  The molecular and structural mechanisms of AlkB’s 
preference on ss- or ds-DNA warrant further investigation. 
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FIGURES  
 
Figure 1. a) Repair mechanism of the AlkB family enzymes on alkyl DNA lesions.  
Adducts m1A and m1G are used here as examples to represent strong and weak 
substrates of AlkB, respectively.  b) The four DNA adducts studied in this work and 
their strand preference (ss- vs ds-DNA) for AlkB to act on them. 
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Figure 2. High resolution triple quadrupole -TOF MS analyses of AlkB repairing 
different alkyl adducts in ss- and ds-DNA.  Data represent the starting material and 
product in their -4 charge envelopes, with the observed m/z values of their 
monoisotopic (all 12C, 14N, 16O, etc.) peaks labeled above each envelope.  The 
percentage of the starting material and product in each reaction is also labeled above 
the corresponding peak envelopes.  The peak near m/z 1228.20 in panel c and d is 
from a non-DNA impurity.  a) AlkB + ss-m1A; b) AlkB + ds-m1A:T; c) AlkB + ss-
m1G; and d) AlkB + ds-m1G:C.   
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Figure 3. Repair efficiency of AlkB on different 16mer adducts in ss- and ds-DNA.  
For each lesion, the extent of repair in ss-DNA is colored in red, the extent of repair in 
ds-DNA with non-mutagenic pairing is colored in yellow, and the extent of repair in 
ds-DNA with mismatch bases is colored in green.  Detailed information of enzyme 
concentrations is listed in Table S3.  The error bars represent the standard deviation 
from triplicate experiments.  The significance of the difference between ss-DNA and 
ds-DNA with non-mutagenic pairing was tested using the Student’s two-tailed t test.  
** indicates p-value <0.01.  a) m1A; b) m3C; c) m1G; and d) m3T.   
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Figure S1. Repair efficiency of ABH2 on different adducts in ss- and ds-DNA. The 
error bars represent the standard deviation from triplicate experiments.  The 
significance of the difference between ss-DNA and ds-DNA with non-mutagenic 
pairing was tested using the Student’s two-tailed t test.  ** indicates p-value <0.01. 
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Figure S2. Repair efficiency of ABH3 on different adducts in ss- and ds-DNA.  The 
error bars represent the standard deviation from triplicate experiments.  The 
significance of the difference between ss-DNA and ds-DNA with non-mutagenic 
pairing was tested using the Student’s two-tailed t test.  ** indicates p-value <0.01. 
** 
** 
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Figure S3. Polyacrylamide gel electrophoresis of purified AlkB protein.   
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Figure S4. Polyacrylamide gel electrophoresis of purified ABH2 protein. 
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Figure S5. Polyacrylamide gel electrophoresis of purified ABH3 protein. 
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Figure S6. Purity test of oligonucleotides containing the four alkyl adducts by HPLC.  
The retention time of the oligos is around 5.0 min. For each test, 100pmol oligo was 
injected.  From top to bottom, the sub-figures represent 16mer oligos containing m1A, 
m3C, m1G, and m3T.  
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Figure S7. Purity test of oligonucleotides containing A/C/G/T in the 17mer 
complementary strands by HPLC.  The retention time of the oligo is around 5.0 min.  
For each test, 100pmol oligo was injected.  From top to bottom, the sub-figures 
represent 17mer oligos containing A, C, G, and T.  
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Figure S8. ESI-TOF analysis of 16mer oligonucleotide containing m1A.  
 
Figure S9. ESI-TOF analysis of 16mer oligonucleotide containing m3C.  
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Figure S10. ESI-TOF analysis of 16mer oligonucleotide containing m1G.  The peak 
at 1228.179 is from an impurity.  The peak at 1228.704 is the monoisotopic peak of 
the 16mer containing m1G.  
 
Figure S11. ESI-TOF analysis of 16mer oligonucleotide containing m3T.  
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Figure S12. ESI-TOF analysis of 17mer oligonucleotide containing A.  
 
 
Figure S13. ESI-TOF analysis of 17mer oligonucleotide containing C.  
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Figure S14. ESI-TOF analysis of 17mer oligonucleotide containing G.  
 
 
Figure S15. ESI-TOF analysis of 17mer oligonucleotide containing T.  
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Figure S16.  Repair efficiency of AlkB on different adducts in ss- and perfect match 
ds-DNA with non-mutagenic pairing and additional 15μM unrelated ss-23mer DNA.  
The error bars represent the standard deviation from triplicate experiments.  The 
significance of the difference between ss-DNA and ds-DNA with non-mutagenic 
pairing was tested using the Student’s two-tailed t test.  * indicates p-value <0.05 and 
** indicates p-value <0.01. 
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TABLES  
Table 1. Initial velocity measurements of AlkB on the four DNA substrates in ss- and 
perfect match ds-DNA.  Each reaction was carried out in triplicate.  The significance 
of the difference between ss- and ds-DNA reactions was tested using the Student’s 
two-tailed t test.  The p-values are statistically significant. 
 
ss-DNA [μM·min-
1] 
ds-DNA [μM·min-
1] 
p-value 
m1A 1.17 ± 0.05 1.03 ± 0.02 0.012 
m3C 1.13 ± 0.01 0.84 ± 0.02 <0.001 
m1G 0.57 ± 0.03 0.88 ± 0.02 <0.001 
m3T 0.03 ± 0.01 0.10 ± 0.01 0.001 
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Table S1. Calculated and observed monoisotopic molecular weight and m/z value of 
oligonucleotides present in the enzyme repair reactions. The sequence of the 16mer 
oligos is 5’-GAAGACCTXGGCGTCC-3’, where X indicates the position of the 
lesions and the repaired products.  The sequence of the 17mer oligos is 5’- 
TGGACGCCYAGGTCTTC-3’, where Y represents the position incorporating the 
complementary bases. 
Lesion or base 
MW (calculated) of 
neutral species 
m/z (calculate) 
-4 charge peak 
m/z (observed) 
-4 charge peak 
16mer m1A 4902.88 1224.71 1224.71 
16mer m3C 4878.87 1218.71 1218.70 
16mer m1G 4918.87 1228.71 1228.70 
16mer m3T 4893.87 1222.46 1222.45 
16mer A 4888.86 1221.21 1221.20 
16mer C 4864.85 1215.20 1215.20 
16mer G 4904.86 1225.21 1225.20 
16mer T 4879.85 1218.95 1218.96 
17mer A 5183.90 1294.97 1294.96 
17mer C 5159.88 1288.96 1288.96 
17mer G 5199.89 1298.97 1298.95 
17mer T 5174.88 1292.71 1292.71 
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Table S2. Repair efficiency of the three enzymes on four lesions (Figure 3).  Each 
repair reaction was carried out in triplicate. 
AlkB repair of indicated lesion in ss-DNA and ds-DNA. 
Lesion 
Repair ratio in ss-DNA and ds-DNA (%)  
ss-DNA lesion+A lesion+C lesion+G lesion+T 
m1A 53.4 ± 1.5 52.7 ± 4.0 39.0 ± 0.2 40.3 ± 1.1 21.8 ± 1.4 
m3C 79.0 ± 1.2 81.4 ± 0.8 70.3 ± 1.7 67.1 ± 1.4 65.8 ± 1.4 
m1G 48.2 ± 1.1 50.0 ± 0.3 69.2 ± 0.9 43.7 ± 1.8 55.5 ± 0.5 
m3T 12.0 ± 0.4 21.0 ± 0.5 27.8 ± 0.3 12.5 ± 0.0 16.8 ± 0.5 
ABH2 repair of indicated lesion in ss-DNA and ds-DNA. 
Lesion 
Repair ratio in ss-DNA and ds-DNA (%) 
ss-DNA lesion+A lesion+C lesion+G lesion+T 
m1A 64.5 ± 1.4 98.3 ± 0.2 96.7 ± 1.0 78.7 ± 1.5 77.9 ± 1.2 
m3C 59.7 ± 0.6 93.5 ± 0.4 84.2 ± 0.5 88.8 ± 1.2 54.0 ± 0.3 
m1G 22.2 ± 0.7 70.9 ± 0.6 62.3 ± 1.2 44.7 ± 0.7 70.7 ± 1.5 
m3T 15.9 ± 1.2 94.1 ± 0.9 92.5 ± 0.7 93.5 ± 0.4 93.3 ± 0.8 
 
ABH3 repair of indicated lesion in ss-DNA and ds-DNA. 
 
Lesion 
Repair ratio in ss-DNA and ds-DNA (%) 
ss-DNA lesion+A lesion+C lesion+G lesion+T 
m1A 72.0 ± 1.5  13.0 ± 0.7 51.3 ± 2.2 9.8 ± 0.8 9.1 ± 0.5 
m3C 57.0 ± 0.4 13.6 ± 0.2 45.2 ± 1.1 10.5 ± 0.5 20.9 ± 0.2 
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Table S3. Enzyme concentrations of the three enzymes in the repair reactions.  For 
each repair reaction, 5 μM 16mer DNA oligo and the corresponding concentration of 
the enzyme in this table were used.  * the repair efficiencies of ABH3 on m1G and 
m3T were extremely low and the products were undetectable even with addition of 
large excess amount of the enzyme, such as adding 5μM enzyme to 5μM DNA 
adducts. 
lesion AlkB (μM) ABH2 (μM) ABH3 (μM) 
m1A 0.25 0.31 0.63 
m3C 0.08 0.31 0.40 
m1G 0.75 5.00 -* 
m3T 1.50 1.25 -* 
 
Table S4. Enzyme concentrations of AlkB in the reactions of measuring the initial 
velocity.  For each repair reaction, 5 μM 16mer DNA oligo and the corresponding 
concentration of AlkB in this table were used. 
Lesion AlkB (μM) 
m1A 0.1 
m3C 0.035 
m1G 2.0 
m3T 1.5 
 
 
 
 
 
81 
 
Table S5. Repair efficiency of the AlkB enzyme on four lesions with additional 15μM 
unrelated 23mer DNA.  The ds-DNA reactions were carried out with the perfect match 
base pairs of each adduct.  The corresponding concentrations of AlkB were listed in 
the table.  Each repair reaction was carried out in triplicate. 
lesion ss-DNA (%) ds-DNA (%) p-value AlkB (μM) 
m1A 56.8 ± 5.5 33.0 ± 0.7 0.016 0.50 
m3C 31.3 ± 0.2 28.8 ± 1.3 0.028 0.15 
m1G 40.3 ± 1.6 49.8 ± 4.4 0.024 2.25 
m3T 13.7± 0.4 41.9 ± 0.8 <0.001 4.50 
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ABSTRACT 
Hydrolysable tannins are a class of polyphenolic compounds commonly found in 
natural products. In this work, we studied the in vitro inhibitory mechanism of six 
molecules in this class on ALKBH2, an Fe(II)/α-ketoglutarate-dependent DNA repair 
enzyme in the AlkB family. We determined the IC50 values of these compounds on 
the repair of 3-methylcytosine, the prototypical substrate of ALKBH2. A structure-
activity relationship was also observed between the strength of inhibition and the 
number of galloyl moieties in a molecule. In addition, we found that the inhibition by 
this class of polyphenolic compounds on ALKBH2 occur through an iron-chelating 
mechanism. 
INTRODUCTION 
Hydrolysable tannins including ellagitannins and gallotannins are a class of 
polyphenolic compounds that are commonly found in variety of fruits and plants, such 
as berries and oak barks.1,2 These molecules share a general structural motif of galloyl 
group(s) and they have been shown to exhibit many health benefits including 
antioxidative, antiproliferative, and neuroprotective effects.3 Recent studies have 
revealed the involvement of hydrolysable tannins, as iron chelators, in mitigating iron-
overload induced hepatotoxicity and neurological disorders.4 Despite the positive 
effects, concerns have been raised on the safety of overconsumption of natural 
products containing hydrolysable tannins, especially with the lack of evidence in the 
relationship between cellular uptake of these compounds and activity of many iron-
related enzymes.  There are about 80 Fe(II)/α-ketoglutarate (αKG)-dependent enzymes 
in human body, including TET, JmjC and AlkB family proteins.5  In this paper, we 
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focus on the DNA repair enzyme ALKBH2 in the AlkB family, which use 
Fe(II)/αKG-dependent mechanism to repair alkyl nucleic acid lesions induced by 
endogenous and environmental alkylating agents (Figure 1a).6,7 
The AlkB family proteins include nine human homologs (ALKBH1-8 and FTO), 
among them ALKBH2 has been identified as the major repair enzyme to lesions in 
both ss- and ds-DNA, and ALKBH3 has activity mainly on lesions in ss-DNA.5,6 A 
number of alkyl substrates have been reported for the AlkB enzymes including 3-
methylcytosine (m3C), 1-methlyadenine (m1A), 1,N6-ethenoadenine, 3,N4-
ethenocytosine, and other alkyl adducts on the DNA bases. Among these adducts, 
m3C and m1A have been demonstrated as the best substrates of AlkB.6,8 Considering 
the important role of the AlkB enzymes in maintaining genome integrity and the 
previous observations of hydrolysable tannins as metal chelators,, we questioned 
whether hydrolysable tannins could affect the activity of the AlkB proteins by 
chelating the cofactor Fe(II) ion. In this study, we investigated the potential of six 
hydrolysable tannins (structures 2 to 7, Figure 1b), as a new class of inhibitor to the 
AlkB enzymes.  We extracted and purified a series of ellagitannins and gallotannins to 
evaluate their inhibitory effects on the repair efficiency of m3C by the ALKBH2 
protein by removing the Fe(II) ion cofactor in the enzymatic reaction. In addition, we 
observed a structure-activity relationship between the strength of inhibition and the 
number of galloyl groups in these hydrolysable tannins. Our results offer a new 
perspective into the potential effect of overtaking hydrolysable tannins that could lead 
to the inhibition of iron-dependent enzymes, which will be confirmed by in vivo 
studies with the consideration of bioavailability and metabolism. 
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EXPERIMENTAL PROCEDURES 
DNA synthesis. Sixteen-mer oligonucleotides with the sequence of 5’-
GAAGACCTXGGCGTCC-3’, where X designates 3-methylcytosine, were 
synthesized by applying automated solid-phase phosphoramidite chemistry on a 
Mermade-4 DNA synthesizer.9 The concentration of oligos was measured by 
NanoDrop (Thermo Scientific) under UV absorbance of 260 nm. The extinction 
coefficient (ε) of 3-methylcytosine lesion is calculated as its unmodified counterpart 
due to the negligible value difference in a 16mer context. All the oligos were purified 
by reverse-phase HPLC with a Phenomenex Luna Semi-Preparative (10 × 250 mm, 5 
μm) C18 column. The solvent A was 100 mM 1:1 triethylamine-acetic acid (TEAA) 
and B was 100% acetonitrile. The oligos were characterized by LC-ESI-TOF-MS (AB 
Sciex) under negative ionization mode, the liquid chromatographic separation was 
conducted using a Phenomenex Luna C18 column (4.6 × 100 mm; 5 μm) at a flow rate 
of 0.4 mL/min. Solvent A was 10 mM ammonium acetate in water, and solvent B was 
100% acetonitrile. 
Protein purification. The ALKBH2 protein was expressed and purified as 
previously described.10 Briefly, the ALKBH2 gene was cloned into the pET28a+ 
vector and then transformed into E. coli BL21 (DE3) pLysS cells for expression. The 
his-tagged proteins were purified by affinity column chromatography using FPLC (GE 
healthcare). Thrombin was added to digest His-tagged proteins overnight followed by 
further purification using ion-exchange chromatography. The purified ALKBH2 
proteins were stored in ALKBH buffer containing 300 mM NaCl, 10% glycerol, 50 
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mM N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid and 1 mM 2-
mercaptoethanol under pH 8.0.  
Enzymatic assay and Inhibition mechanism study.  For the enzyme inhibition 
studies, 5 μM of single-stranded m3C DNA oligonucleotides were incubated with 1.25 
μM of ALKBH2 proteins in 46.5 mM HEPES buffer (pH8.0) containing 50 μM αKG, 
5 μM Fe (NH4)2(SO4)2 and 1.86 mM ascorbic acid in a 20 μL reaction volume at 
37°C for 1 hour.2 To test the IC50 values, the concentrations of hydrolysable tannins 
used were optimized individually to achieve the inhibition percentages between range 
of 0% to 100%. For the inhibition mechanism studies, the concentration of αKG was 
fixed to 93 μM, and different concentrations of Fe (NH4)2(SO4)2 (5, 10, 20, 40, 80 
μM) were used for Fe(II) chelator test. In contrast, varying concentrations of αKG (50, 
100, 200, 400, 800 μM) and fixed 10 μM of Fe (NH4)2(SO4)2 were used for the α-
ketoglutarate competitor test. The enzyme activity was inactivated by adding 10mM 
EDTA followed by heating up to 95°C for 5 min. The analyses were performed by 
HPLC and all data represent the mean (± standard deviation, SD) of three independent 
experiments.  
HPLC analysis. m3C and its repaired product C were analyzed by using a 
DNApac PA-100 anion-exchange column (4 x 250 mm, 13 μm) with solvent A as 
water and solvent B as 1.5 M ammonium acetate in water. The flow rate was at 1.0 
mL/min.  A solvent gradient was carried out under the following conditions: 60% of B 
for 6 min, 60%-80% for 0.5 min, 80% for 1 min, 80%-60% for 0.5 min, 60% for 4 
min.  
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Materials. Rhein (1), gallic acid (2), ellagic acid (3) and tannic acid (7) were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).  Ellagitannin 
(punicalagin 6) was isolated from a commercially available pomegranate extract 
(PomellaTM) provided by Verdure Sciences (Noblesville, IN, USA) using our 
previously reported methods.11 Gallotannins including ginnalin A (4) and pentagalloyl 
glucose (5) were isolated from a red maple leaves extract and sumac fruit extract, 
respectively, as we previously reported.12,13   
RESULTS AND DISCUSSION 
To test the inhibitory effects of hydrolysable tannins on ALKBH2, 16mer 
oligonucleotides bearing a site-specific m3C adduct, the primary substrate of 
ALKBH2, were synthesized by using solid-phase phosphoramidite chemistry.9,14 The 
recombinant human ALKBH2 protein was expressed and purified according to 
previous studies.10,15 Then the repair efficiency of ALKBH2 on m3C was assessed.  
For the enzymatic reactions, the m3C-containing oligonucleotides were incubated with 
ALKBH2 in the presence of two cofactors (αKG and Fe(II) ion) and other necessary 
reagents and buffers (see Experimental section in SI for details), and the repair ratio of 
m3C was quantified by HPLC after reaction. We used 5.0 μM DNA and 1.25 μM 
ALKBH2 for a typical enzymatic reaction to test the inhibition of different 
compounds, these concentrations are similar to the conditions previously reported.15 
The IC50 values of the six hydrolysable tannins on inhibition of ALKBH2 were 
determined. We prepared these compound as previously reported.11,12,16  Rhein 
(compound 1, Figure 1b), a well-known inhibitor to the AlkB family enzymes was 
served as a positive control.17  The concentrations of rhein varied from 0 to 150 µM 
 
98 
 
and the IC50 was found as 42.0 μM (Figure S1), which is comparable to the values on 
inhibiting AlkB and FTO reported by Li et al.17 For the hydrolysable tannins, the 
concentrations were tested between 0 and 80 µM (Figures S2 to S7).  The IC50 values 
of compound 2 to 7 were found from 3.9 to 38.2 μM (Table1 and Figures S2 to S7). 
Interestingly, based on the structures of these hydrolysable tannins, we found a 
correlation of their structural features to their IC50 values: as the number of galloyl 
group in the molecule increases, the IC50 value decreases (Table 1).  For example, the 
one galloyl unit containing compound 2 has IC50 38.2 μM, the five galloyl unit 
containing compound 5 has IC50 18.9 μM, and the ten galloyl unit containing 
compound 7 has IC50 3.9 μM.  Compounds 3 and 4 have two galloyl units and they 
have similar IC50 values (25.5 and 22.6 μM, respectively). These results indicate that 
the basic galloyl unit of these derivatives are potentially the structural motif 
responsible for the inhibitory effects. 
We further explored the inhibition mechanism of compounds 1 to 7 on the DNA 
repair by ALKBH2.  Previously, rhein has been reported as an inhibitor to AlkB and 
FTO by competitively replacing αKG in the active site.17,18 And hydrolysable tannins, 
including tannic acid (compound 7), have been reported to ameliorate Fe(II) ion and 
reactive oxygen species induced neurological diseases.19 In addition, tannic acid has 
been reported to mitigate iron-overload by its chelating ability through the neighboring 
phenol hydroxyl groups.4  We wanted to investigate the inhibitory mechanisms of the 
hydrolysable tannins and chose tannic acid because of its reported activities and the 
most galloyl groups possessed in the molecule. 
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We varied the concentration of αKG and Fe(II) ion in the reactions without any 
inhibitor, and with rhein or compound 7.  For the reactions without the inhibitor, small 
variations on the reactivity were found with αKG changing from 50 to 800 µM (89% 
to 99%, control in Figure 2a) and Fe(II) ion changing from 5 to 80 µM (staying around 
93%, control in Figure 2b).  First we tested the reactivity change with different 
concentrations of αKG with a fixed Fe(II) ion concentration of 10 µM. When 50 µM 
of rhein was added to the reaction media, we found the repair ratio decreased to 30% 
with 50 µM αKG.  As the amount of αKG increased up to 800 µM, the repair 
efficiency was recovered in a concentration-dependent manner (Figure 2a).  Then we 
tested the reactivity change with different concentrations of Fe(II) ion (from 5 to 80 
µM) with a fixed αKG concentration of 93 µM.  The reactions with 50 µM rhein all 
had repair efficiency around 36% and showed no significant change even with the 
increment of Fe(II) ion to 80 µM (Figure 2b).  These observations are consistent with 
previously reported data of rhein and show that it is a competitive inhibitor to αKG but 
not an Fe(II) ion chelator.17,18  For compound 7 under variable concentrations of αKG, 
all of the reactions with 2 µM of it had a decreased repair efficiency around 25% and 
did not vary significantly with the increment of αKG even to 800 µM (Figure 2a, 
Fe(II) ion kept at 10 µM).  For the reactions with varying concentrations of Fe(II) ion, 
the reactivity was decreased to 5% with 5 µM Fe(II) ion and was restored in a 
concentration-dependent manner as Fe(II) ion stepwisely increased up to 80 µM 
(Figure 2b, αKG kept at 93 µM).  These data indicate that compound 7 is an Fe(II) ion 
chelator but not a competitive inhibitor to αKG.     
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In this study, we investigated hydrolysable tannins as a new class of natural 
product inhibitors for ALKBH2, the major human DNA repair enzyme in the AlkB 
family. Hydrolysable tannins have been identified as antioxidative, antiproliferative 
and neuroprotective agents. Here, we discovered that these compounds are Fe(II) ion 
chelators that can decrease the level of free Fe(II) ion, which is critical for the catalytic 
activity of the AlkB family enzymes.  At a concentration higher than the Fe(II) ion 
level, the reactivity of the AlkB enzymes might be inhibited.  It is possible that the 
overconsumption of hydrolysable tannins may affect iron homeostasis in the body 
leading to the dysfunction of iron-dependent proteins, such as the AlkB homologs and 
other Fe(II)/αKG-dependent enzymes.  Further studies are necessary to confirm these 
observations. 
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FIGURES 
 
 
Figure 1. Repair mechanism of the AlkB family enzymes and structures of the 
hydrolysable tannins and rhein.    
 
 
102 
 
 
Figure 2. Inhibition of ALKBH2 repair reactions by tannic acid and rhein (control: no 
inhibitor added). 
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Figure S1. Data for determining the IC50 value of compound 1 (Rhein). 
 
 
Figure S2. Data for determining the IC50 value of compound 2 (gallic acid). 
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Figure S3. Data for determining the IC50 value of compound 3 (ellagic acid). 
 
Figure S4. Data for determining the IC50 value of compound 4 (ginnalin acid). 
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Figure S5. Data for determining the IC50 value of compound 5 (pentagalloyl glucose). 
 
Figure S6. Data for determining the IC50 value of compound 6 (punicalagin). 
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Figure S7. Data for determining the IC50 value of compound 7 (tannic acid). 
 
TABLES 
Table 1.  IC50 values of hydrolysable tannins inhibiting the ALKBH2 enzyme. 
compound IC50 (µM) galloyl units 
2 38.2 1 
3 25.5 2 
4 22.6 2 
5 18.9 5 
6 8.1 6 
7 3.9 10 
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ABSTRACT 
Reducing sugars non-enzymatically glycate proteins and nucleic acids to form 
glycation adducts. Previously, glucose and glucose-6-phosphate have been shown to 
glycate lysine residues of protein to form Amadori adducts. As a glycating agent with 
multiple-fold higher reactivity and much more abundant cellular concentration than 
glucose, glucose-6-phosphate has been proposed to glycate DNA and cause 
genotoxicity.  Due to the unstable nature of the Amadori adducts and the presence of 
cellular DNA repair pathways, it is challenging to study their toxic and mutagenic 
properties in cell.  Therefore, the specific biological outcomes of these adducts remain 
unclear. In this work, we used chemical and genetic approaches to study the biological 
consequences, such as replication block and mutations, of Amadori DNA adducts in a 
site-specific manner. Our data showed that Amadori DNA adducts arising from 
glucose-6-phosphate on dG can induce G to T and single nucleotide deletion, which 
may lead to devastating biological consequences if left unrepaired. 
INTRODUCTION 
Reducing sugars and their metabolic derivatives (e.g. glucose, glucose 6-
phosphate, methylglyoxal, and glyoxal) can nonenzymatically react with free amino 
groups of biomacromolecules, such as proteins and nucleic acids, to induce 
glycation.1–3  Among these cellular glycating agents, methylglyoxal and glyoxal are 
byproducts of sugar metabolism which are considered as toxins, whereas glucose or 
glucose 6-phosphate (Glu-6-P) are thought to be non-toxic because they are essential 
metabolic intermediates to supply energy and precursors for biosynthetic pathways in 
nearly all organisms.  Although D-glucose has a high concentration in blood, it is 
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mostly phosphorylated to Glu-6-P after it entering cell (Fig. 1).  Thus, Glu-6-P is the 
most abundant reducing sugar in cell (~ mM level) which can be further elevated 
under abnormal metabolic conditions.1,4 
Previously, Glu-6-P and glucose have been shown to glycate lysine residues of 
protein to form  fructosamine 6-phosphate (FN6P) and fructosamine products, 
respectively.5,6  And these adducts are involved in the pathogenesis of many diseases, 
such as aging and cardiovascular diseases due to accumulation of the unrepaired 
glycated-proteins.2,2  Recent studies showed that protein FN6P and fructosamine 
adducts can be repaired by MDP-1/FN3K mechanism, which has been hypothesized as 
the major detoxification pathway for Glu-6-P induced protein glycation.7,8  As a 
glycating agent with multiple-fold higher activity than glucose, Glu-6-P has been 
demonstrated to glycate DNA and lead to cytotoxicity and mutagenesis.  DNA 
glycation has been shown to lead to increased cytotoxicity, strand breaks, and 
mutation frequency that are thought to be associated with cancer, neurological 
disorders, and aging related diseases.9,2  The extent of DNA alternation appears to be 
dependent on the type of nucleobase involved in the modification.  Among the three 
amino group-containing nucleobases, guanine is most vulnerable to glycating agents; 
and N2-dG adducts are the primary source of DNA glycation products.2,5    
Glu-6-P glycates DNA with the formation of unstable Schiff base, which rapidly 
undergoes structural rearrangement and thereby generate an acyclic Amadori product 
(N2-Fructosamine 6-Phosphate-Deoxygunosine, N2-FN6P-dG), the acyclic N2-FN6P-
dG adduct undergoes further ring closure at O-5 with the C-2 carbonyl group to 
generate more stable α and β configurations (Fig. 1).  Previous cellular study reported 
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that elevated intracellular Glu-6-P levels could increase plasmid mutations in 
glycolytic mutant bacteria.10  Also, Bucala et al. examined the mutagenic effect of 
Glu-6-P-induced adducts in pBR32 DNA plasmid in E. coli, and a number of mutant 
plasmids were observed to have undergone gross DNA alterations, including 
mutations, insertions and deletions, as well as the development of multiple species 
originating from a single cell.11  These studies have demonstrated that DNA glycation 
by Glu-6-P can cause damages to genome and lead to mutagenicity.  However, with 
the complexity of the formation and unstable nature of Glu-6-P glycation adducts as 
well as the potential cellular repair mechanisms involved, it is challenging to study the 
mutagenic properties of these adducts.  However, with the complexity of the formation 
and unstable nature of Glu-6-P glycation adducts as well as the potential cellular repair 
mechanisms involved, it is challenging to study the mutagenic properties of these 
adducts.  For these reasons, the exact biological consequences of glycation DNA 
adducts from Glu-6-P are still unclear.   
In this paper, we used chemical and genetic methods to study the biological 
consequences, such as replication block and mutagenesis, of these glycation adducts in 
a site-specific manner. We chemically synthesized N2-FN6P-dG adducts and site-
specifically incorporated them into single-stranded M13 vectors, ant the cytotoxic and 
mutagenic properties of the adducts were determined in E. coli cells. Our results, for 
the first time, revealed that N2-FN6P-dG adducts cause strong DNA replication block 
as well as significant amount of G → T and single nucleotide deletion mutations in 
cell. These observations indicate that FN6P DNA glycation products arising from Glu-
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6-P could lead to genome instability if left unrepaired, thereby affecting the genome 
integrity of organisms.  
EXPERIMENTAL PROCEDURES 
Chemical Synthesis and Characterization of N2-FN6P-dG Glycation 
Products.  Thirteen-mer unmodified oligonucleotides with the sequence 5’-
TTTTTTGTTTTTT-3’ were synthesized by using solid-phase phosphoramidite 
chemistry on a DNA synthesizer (Bioautomation). The sequence was designed to 
harbor only one guanine base to ensure the site-specific incorporation of N2-FN6P-dG 
glycation adduct. A concentration of 200 µM 13mer oligos was incubated with 1 M of 
D-Glucose 6-phosphate (Roche) under physiological conditions (pH 7.4 in PBS buffer 
at 37 °C) for 14 days, two major N2-FN6P-dG products were observed. Studies have 
shown that the glycation process was accelerated under elevated pH and temperature 
1,12. An optimized reaction condition (pH 9.5 in 0.1 M sodium borate buffer at 80 °C) 
was used to shorten the reaction time (12 h) and increase the yield of glycation 
products, two N2-FN6P-dG products were observed with HPLC retention time and 
MW matching the two glycation products formed under physiological conditions. The 
resulting two N2-FN6P-dG glycation products were separated and purified by a 
DNAPac PA100 anion-exchange oligonucleotide column (13 µm, 22 x 250 mm, 
Thermo Scientific) with two solvents. Solvent A was water, and solvent B was 1.5 M 
ammonium acetate. The purified glycation products were characterized by high-
resolution triple-TOF MS (AB Sciex).  
Construction of M13 Vectors Containing Site-Specific Incorporation of N2-
FN6P-dG Adducts.  The M13mp7(L2) viral genomes were prepared with site-
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specific incorporation of N2-FN6P-dG or adduct-free N2-dG by following the 
procedures adopted from Delaney and Essigmann.13  Specifically, 1000 pmol of 13mer 
adduct carrying ss-oligos (5’-TTTTTTXTTTTTT-3’, where “X” designates  N2-FN6P-
dG or N2-dG) and 1050 pmol of 21mer barcode ss-oligos (1st barcode sequence: 5’-
TACCGTCGBBBCGCGCATGCA-3’, and 2nd barcode sequence: 5’-
TCTCGAGTGBBBCGTCAGCAC-3’, where BBB serves as the barcode location for 
next-generation sequencing purpose that was not applied in this work) were 5’-
phosphorylated in a 50 µl solution containing 1mM ATP, 1×T4 polynucleotide kinase 
buffer, and 30 units of polynucleotide kinase at 37 °C for 1 h. The 5’-phosphorylated 
13mer strand and two 21mer strands were annealed with two scaffolds (1100pmol of 
15mer Scaffold I: 5’-GCGCGTACGTAAAAA-3’, and 1100pmol of 14mer Scaffold II: 
5’-AAAAAAGAGCTCAC-3’) and further elongated into a 55mer strand by using 
1200 units of T4 DNA ligase at 16 °C for 3 h. The ligated 55mer oligos were purified 
by 15% PAGE-urea gel and the concentration was quantified by UV absorbance 
measurement at 260 nm.  The ligated 55mer oligos (75 pmol) were annealed with 30 
pmol of ss-M13mp7(L2) vectors (linearized by XX units of EcoRI at XX °C for XX h) 
in the presence of two scaffolds (48 pmol of 28mer Scaffold III: 5’-
CGATACTGGTACTAAGTCACATGGCAGC-3’, and 48 pmol of 29mer Scaffold IV: 
5’-GCAGTCGTGTTAAGTGACCGGCAGCAAAA-3’) and then ligated by T4 ligase 
at 16 °C for 12 h.  20units λ exonuclease and 30 units of RecJf exonuclease were 
subsequently added to the resulting mixture and incubated at 37 °C for 5 h. The 
mixture was extracted with phenol/chloroform/isoamyl alcohol (25/24/1, vol), and the 
aqueous phase was precipitated by 100% ethanol and the DNA pellet (genome) was 
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resuspended in nuclease-free water. The constructed genomes were normalized against 
an adduct-free competitor genome ligated with a 58mer competitor strand (by 
inserting a 16mer ss-oligo: 5’-TTTTTTGTTTTTTTTT-3’).   
Transfection of E. coli Cells with M13 Vectors Containing N2-FN6P-dG 
adducts. The electrocompetent AB1157 E. coli cells were electroporated (at 2.5kV) 
with M13 genomes containing N2-FN6P-dG or adduct-free N2-dG which were pre-
mixed with the competitor genomes at a ratio of 4:1. The E. coli cells were then 
transferred into 1 ml SOC medium and incubated at 37 °C for 1 h followed by 
transferring into 10 ml LB medium for an additional incubation of 6 h, after which the 
resulting phages were collected from the supernatant of culture medium by 
centrifuging at 4700 rpm for 15 min. The phages were further amplified by SCS110 E. 
coli cells to increase the progeny genome percentage over adduct-carrying genomes. 
The final amplified phages were recovered by centrifuging at 4700 rpm for 15 min, 
and the M13 genomes were extracted with a QIAprep 2.0 spin column by following 
manufacturer’s guidance. 
LC-MS Based Bypass Efficiency and Mutation Frequency Assays. A 
competitor gapped plasmid (with a ligation of 16mer oligonucleotide 5’-
TTTTTTGTTTTTTTTT-3’) with three bases longer than the adduct-containing 
plasmid was used as an internal control.  The resulting progeny genomes after 
replication were extracted according to the instruction of QIAGEN DNA extraction kit.  
The region of interest in the genome was amplified with two primers (Primer F: 5'-
GCTATGACCATGATTCAGTGTACCGTCG-3', Primer R: 5'-AAAACGACGGCC 
AGTGAATTGTGCTGACG-3') by PCR.  The PCR products were purified by 
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QIAquick PCR Purification kit.  For the LC-MS analysis, the PCR fragments were 
digested with 40 units of Xhol and 30 units of SphI enzymes in 50µL of CutSmart 
buffer at 37 °C for 3 h, flowed by heating up to 65 °C for 20 min to deactivate the 
restriction enzymes. The resulting oligonucleotides were desalted and analyzed by LC-
MS. The following LC-MS conditions were used: the LC separation was carried out 
by using a Thermo Acclaim PolarAdvantage II C18 column (3µm, 2.1 x 250mm); the 
flow rate was 100µL; a 5min of gradient of 25% was used to introduce sample 
followed by a 30 min of 25%-50% methanol in 400mM HFIP buffer (pH 7.0) for 
separation. ESI was conducted by using a needle voltage of 4.0 kV in a negative mode. 
The heater was set at 300 °C. The nebulizer gas was 40 psi; the heater gas was 40 psi; 
the curtain gas was 25 psi; the declustering potential was −220 V; and the collision 
energy was −10 V.  For the calculation of bypass efficiency, the formula %bypass = 
(adduct oligo signal/competitor signal)/(non-adduct signal/its competitor signal) was 
used. 
Statistical Analyses.  Statistical analysis was conducted by software IBM SPSS 
Statistics 23 and Microsoft Excel 2016. Statistical significance for data between two 
groups was characterized with a two-tailed Student’s t test. P-values < 0.05 were 
considered statistically significant. 
RESULTS 
Chemical Synthesis and Characterization of N2-FN6P-dG Adducts.  To 
synthesize N2-FN6P-dG glycation adducts, we first tested the glycation of DNA under 
physiological conditions (37 °C, and pH 7.4 in PBS buffer) by incubating 200 µM of 
13mer oligonucleotide (5’-TTTTTTGTTTTTT-3’) with 1 M Glu-6-P for 14 days.  
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AEX-HPLC analysis have revealed the formation of two major products (peak1 and 2 
in Fig. 2b), which were later characterized as α and β anomers of the N2-FN6P-dG 
adducts in the 13mer context. However, the yield of the products was low (less than 
10%), which did not meet the amount of material required for the subsequent 
biological studies.  As the glycation rate of nucleic acids by reducing sugars was 
reported to be dependent on two major factors: pH and temperature,12,14  we optimized 
the reaction condition by applying pH 9.5 under 80 °C. We monitored the formation of 
glycation products after 8 hours of incubation, and the results showed that the reaction 
was greatly accelerated and could be prepared on a large scale (Fig. 2a).  We then 
conducted the purification for the two glycation products by AEX-HPLC (Fig. 3a), 
and the HPLC chromatogram indicated that the two peaks were well separated (Fig. 3c 
and 3d).  As the glycation process is reversible, we also tested the stability of the two 
products by incubating them under physiological conditions for 4 days, some of the 
two products (Fig. 3e for peak 1 and 3f for peak 2) were converted back to the starting 
material 13mer G (Fig. 3b); these observations are consistent with the previous studies 
that the DNA glycation of Amadori products are reversible to unmodified DNA 
bases.15  In addition, we compared the reactivity of different nucleobases to Glu-6-P 
under the optimized reaction condition. We quantified the glycation products 
formation for the 13mer oligos containing dA, dC, dG and dT nucleobase respectively. 
The results showed that 13mer G exhibited highest reactivity with 23.1% glycation 
conversion after 8 h, whereas 13mer A and 13mer C had only 1.6% and 0.8%, there 
was no glycation on dT (Fig. 4).  
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After synthesis, we observed the formation of two major glycation adducts (Fig 2, 
and Fig 3a) from the incubation of Glu-6-P with DNA oligos. To identify the MW of 
the two adducts, the modified oligos were analyzed by high-resolution MS.  The 
13mer glycated oligo (peak 1 in Fig. 3c) showed a good signal at m/z of 1384.8857 at 
the -3 charged envelope of mass spectrum (Fig. 5a).  The observed m/z matches the 
theoretical calculation of m/z of 1384.8816 for N2-FN6P-dG adduct formation at X 
location of the starting material sequence (5’-TTTTTTXTTTTTT-3’). Similarly, we 
observed identical MW for the second glycation adduct (peak 2 in Fig. 3d, MS data 
not shown). These results indicated the two glycation products were α and β anomers 
from ring closure of Amadori product at O-5 with the C-2 carbonyl group (Fig. 1).  To 
further confirm the identity of the adducts, we conducted nuclease digestion and 
dephosphorylation of the purified N2-FN6P-dG adduct-containing oligos into single 
nucleosides, then analyzed the highly hydrophilic adduct-carrying dG by HILIC-LC-
MS.  By using a combination of DNase I, phosphodiesterase I, and alkaline 
phosphatase to digest the 13mer sequence into single nucleosides,16–18  we were able 
to observe the digested adduct-modified nucleoside at m/z 430.1647 (positive mode, 
+H, 430.1574 for theoretical m/z); this species was generated from the enzymatic 
dephosphorylation of N2-FN6P-dG into N2-Fructosamine-dG (Fig. 5b, representative 
MS data for peak 1 digestion in Fig. 3c). In addition, no thymidine modifications have 
been observed in the 13mer sequence. These observations together supported that the 
glycation products were N2-FN6P-dG adducts from Glu-6-P (Fig. 1). 
Replication Block and Mutagenicity Assays of N2-FN6P-dG Adducts.  We 
next determined how the presence of N2-FN6P-dG adducts affect DNA replication, 
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and what biological outcomes are involved in polymerase bypassing these adducts in 
cell.  To this end, we carried out site-specific detection of replication block and 
mutagenesis adopted from Essigmann lab 13,19 for the two N2-FN6P-dG adducts. We 
ligated the two adduct-containing 13mer oligos into single-stranded M13 vector 
respectively (Fig. 6), and tested the bypass efficiency and mutation frequency of them 
in E. coli cells. The data obtained from quantitative LC-MS analysis showed adduct-1 
with a bypass efficiency of only 22% comparing to unmodified guanine as 100%, and 
adduct-2 with a bypass efficiency of 24% (Fig. 7, top). These results indicated that the 
N2-FN6P-dG adducts are strong blocks to DNA replication. We subsequently 
quantified the mutation frequency of the two adducts, adduct 1 (Fig. 7, bottom) 
exhibited strong G to T mutation (26%) and -1 deletion of dG base (30%). Similarly, 
adduct-2 had G to T mutation of 16% and -1 deletion of dG of 36%. These results 
demonstrated that N2-FN6P-dG adducts can cause strong mutagenicity. 
DISCUSSION 
Glu-6-P is an important glycolysis intermediate which constitutes a dominant 
endogenous reducing sugar metabolite.  Previous studies on its cellular glycation 
outcomes demonstrated that the dysregulation of Glu-6-P is associated with 
genotoxicity including insertion, deletion, and point mutations10,11.   However, neither 
the exact mutation patterns of the glycation nor the specific identity of these glycation 
adducts were assessed.  This is challenging presumably that, first, cellular glycation 
process is complex due to the many types of glycation adducts formed; second, most 
of these adducts are unstable and could be only existed in transition state; third, 
several competing DNA repair pathways are involved in removing these adducts. To 
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this end, we chemically synthesized and characterized the DNA glycation adducts 
arising from Glu-6-P to confirm their identity. Furthermore, their stability was 
evaluated and proper assays were accommodated to test their biological consequences 
during DNA replication. 
Cellular DNA replication study using M13 vector with site-specific incorporation 
of N2-FN6P-dG adducts revealed that the two anomers exhibited strong block (22% 
and 24% bypass respectively) to polymerase comparing to dG (100% bypass).  This 
result suggests that the two bulky FN6P adducts are poorly tolerated by replication and 
translesion polymerases, and the two glycation adducts occurring at N2 of Watson-
Crick base paring face of dG may impose a large steric hindrance to DNA replication.  
On the other hand, our mutagenicity test demonstrated that the two N2-FN6P-dG 
adducts induced significant G to T and single nucleotide deletion mutations (26% G 
→T, 30% -1 G for adduct-1, 16% G →T, 36% -1 G for adduct-2) comparing to dG (no 
mutations detected). These observations indicate the bypass of the two glycation 
adducts by polymerase is error-prone and in a low fidelity manner.  Previously, Yuan 
et al. have identified methylglyoxal induced N2-carboxyethyl-dG DNA glycation 
adducts are weakly mutagenic and only lead to minor G to T mutation (<3%); besides, 
they have found that the bypass of these adducts are well tolerated by DinB 
(polymerase IV) in E. coli cells2.  There are a number of previous findings that DinB 
is capable of bypassing many N2-dG adducts13,20–22, we doubted that this polymerase 
may also be involved in bypassing N2-FN6P-dG adducts. We performed bypass and 
mutagenesis studies in ΔdinB (pol IV-deficient) E. coli cells. However, results 
obtained from these studies did not show a significant difference of bypass efficiency 
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compared to wild-type cells (data not shown). Future experiments in testing other 
translesion polymerases, such as pol II and pol V, may provide insights into the 
detailed cellular bypass mechanisms on these N2-FN6P-dG adducts.  
Taken together, the results presented in current study provide important evidence 
showing that N2-FN6P-dG adducts arising from Glu-6-P, could lead to strong 
replication block and mutagenicity if left unrepaired, thereby affecting the genome 
integrity of organisms. In addition, Glu-6-P, cellular fructose 6-phosphate (Fru-6-P, 
µM level) and ribose 5-phosphate (Rib-5-P, µM level) are also highly reactive 
glycating agents.23  The two molecules are 1260 fold for Fru-6-P and 1878 fold for 
Rib-5-P more powerful than glucose for glycating DNA.24  The deleterious biological 
effects generated from these reducing sugar metabolites may represent a unique 
perspective to study mutagenesis of endogenous molecules. 
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FIGURES 
 
Figure 1. DNA glycation adducts generated from glucose 6-phosphate and their 
biological implications in cell replication and diseases. 
 
 
 
125 
 
 
Figure. 2. HPLC separations of glycation oligos generated under a) optimized 
condition and b) physiological condition. 
 
Figure. 3. Separations of DNA oligos by AEX-HPLC. a) reaction mixture, b) 13mer 
starting material, c) purified adduct-1, d) purified adduct-2, e) adduct-1 and f) purified 
adduct-2 incubated under 37 ℃ and pH 7.4 for 4 days. 
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Figure. 4.  Glycation adduct formation on four nucleobases. 
 
 
Figure. 5.  ESI-TOF analysis of a) the N2-FN6P-dG containing 13mer oligo; b) N2-
FN6P-dG nucleoside product generated from enzymatic digestion and 
dephosphorylation. 
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Figure. 6.  Genome construction of vectors containing glycation adducts for E. coli 
assays. 
 
Figure. 7.  In cell demonstration of the bypass (top) and mutagenicity (bottom) of the 
glycation adducts. 
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